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RESUMEN 
 
INTRODUCCIÓN 
Desde que Robert Koch descubriera Mycobacterium tuberculosis en 1882 hasta hoy, 
más de 150 especies del género Mycobacterium han sido descritas. Algunas micobacterias 
son virulentas y provocan enfermedades en multitud de individuos. Sin embargo, la mayoría 
de las micobacterias son poco virulentas y pueden encontrarse en el medio ambiente, por lo 
que son llamadas micobacterias ambientales. Las enfermedades por micobacterias en el 
humano pueden estar causadas por la virulencia del microorganismo o por una 
susceptibilidad a las micobacterias intrínseca del individuo, conocida como 
inmunodeficiencia. Las inmunodeficiencias pueden ser secundarias (también llamadas 
adquiridas) o primarias, dependiendo de si la infección por micobacteria es una consecuencia 
indirecta o directa del defecto. Las inmunodeficiencias que confieren enfermedades por 
micobacterias son defectos que afectan a la interacción entre células presentadoras de 
antígeno y células efectoras del sistema inmune. Los individuos afectados por 
inmunodeficiencias primarias pueden sufrir infecciones de un espectro amplio o reducido. 
Aquellos con predisposición a un espectro reducido de infecciones pueden tener infecciones 
por uno o dos microorganismos, entre los que se encuentran las micobacterias. Dentro de esta 
categoría se encuentra la susceptibilidad mendeliana a micobacterias (MSMD por sus siglas 
en inglés), donde los individuos afectados están predispuestos a infecciones por 
micobacterias que pueden estar acompañadas, o no, de infecciones por otros 
microorganismos.  
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OBJETIVOS Y METODOLOGÍA 
 Los pacientes susceptibles a enfermedades por micobacterias, especialmente aquellas 
de poca virulencia, requieren de un diagnóstico genético y de la caracterización del defecto 
genético para poder brindarles un tratamiento personalizado y consejo genético. Mediante el 
uso de secuenciación de última generación y secuenciación Sanger se hallaron mutaciones 
en genes asociados con infecciones por micobacterias, IFNGR2 y GATA2 en concreto, que 
se consideraron patogénicas y se caracterizaron. Para demostrar su patogenicidad se 
utilizaron un sistema de sobreexpresión, células inmortalizadas y sangre de los pacientes 
afectados. Se realizaron ensayos de tipo luciferasa o cambio en la corrida electroforética 
(EMSA, por sus siglas en inglés) para caracterizar estas mutaciones. Además, se utilizaron 
herramientas bioinformáticas para predecir in silico la consecuencia de las mutaciones 
encontradas.  
 
RESULTADOS Y DISCUSIÓN 
 Se hallaron dos nuevas mutaciones en IFNGR2, 10 mutaciones conocidas y una nueva 
mutación en GATA2. Para IFNGR2 se estudiaron tres pacientes con MSMD, dos hermanos 
procedentes de Turquía y un individuo de la India, mediante secuenciación del exoma 
completo (WES, por sus siglas en inglés). Se hallaron dos mutaciones en homocigosis en 
IFNGR2, una mutación cambio de sentido afectando al codón de inicio del gen (c.1A>G) en 
los dos hermanos de Turquía, y otra una deleción de la base inmediatamente posterior al 
codón de inicio del gen (c.4delC) causando un cambio de lectura del gen en el tercer 
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individuo. Dada la localización de estas dos mutaciones se esperaba que la respuesta a IFN-
γ estuviera totalmente abolida. Sin embargo, se observó por sobreexpresión que ambos 
mutantes daban lugar a la expresión reducida de la proteína completa de IFN-γR2 y que eran 
capaces de responder levemente a IFN-γ. En vistas de estos resultados se estudió la respuesta 
a IFN-γ en células inmortalizadas de los pacientes con la mutación c.1A>G. Los fibroblastos 
SV40 de estos pacientes mostraron una respuesta débil a IFN-γ, mientras que las células B 
transformadas con el virus Epstein Barr mostraron una respuesta prácticamente abolida. Para 
confirmar estos resultados se estudiaron linfocitos T primarios y macrófagos derivados de 
monocitos de los pacientes con la mutación c.1A>G. Estas células mostraron una respuesta 
débil a IFN-γ, como se observó en sobrexpresión y en células inmortalizadas. Finalmente, se 
observó que la proteína IFN-γR2 residual generada por ambos mutantes era producida por la 
iniciación de la traducción entre el segundo y noveno codón no-AUG dentro del péptido 
señal. Un péptido señal más corto parece ser suficiente para pasar por las vías de secreción. 
 Para GATA2 se reclutaron 14 probandos con infecciones por micobacterias. Cada uno 
de estos individuos presentaba una mutación germinal en heterocigosis en GATA2 de entre 
las 11 halladas en total, una de las cuales nunca había sido reportada. Tres familiares de estos 
individuos también sufrieron infecciones por micobacterias y eran portadores de una de las 
mutaciones halladas, llegando a un total de 17 pacientes con deficiencia por GATA2. Las 11 
mutaciones fueron estudiadas en un sistema de sobreexpresión, donde se observó que 10 de 
ellas no producían GATA2 correctamente. Mediante la caracterización de estas mutaciones 
se observó que siete de las mutaciones eran pérdida de función y cuatro eran hipomórficas. 
Además, el estudio de mecanismo de dominancia desveló que ninguna mutación actuaba en 
dominancia negativa y, se demostró que GATA2 evolucionó mediante selección purificadora. 
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Esto sugiere que la deficiencia de GATA2 actúa por haploinsuficiencia. Los pacientes 
sufrieron infecciones por diferentes especies de micobacterias, predominantemente dos 
micobacterias ambientales (M. avium y M. kansasii) y M. tuberculosis. La infección por 
micobacteria fue la primera manifestación clínica en 10 de los pacientes, y la mayoría de los 
pacientes sufrieron infecciones por otros microorganismos como bacterias piógenas, hongos 
y virus. En estos pacientes también se observaron problemas hematológicos como 
monocitopenia, mielodisplasia y leucemia mieloide aguda. Entre los familiares se observó 
que 16 eran portadores de una mutación en GATA2 pero permanecían completamente 
asintomáticos, lo que llevó al estudio de la penetrancia de la deficiencia de GATA2, 
concluyendo que es incompleta. Además, se estudió la penetrancia para las infecciones por 
micobacterias, que resultó ser similar a la penetrancia de otras manifestaciones clínicas 
asociadas con la deficiencia de GATA2. 
 
CONCLUSIONES  
 La caracterización de mutaciones germinales en IFNGR2 y GATA2 ha permitido 
tratar y aconsejar a los pacientes con enfermedades por micobacterias. Las dos mutaciones 
descritas en IFNGR2 son la primera muestra de una deficiencia cuantitativa, en vez de 
cualitativa, en un defecto parcial de IFN-γR2. Su impacto a nivel clínico se encuentra entre 
los pacientes con una deficiencia completa de IFN-γR2 y aquellos con una deficiencia 
parcial. Por otro lado, la evaluación de las mutaciones en GATA2 ha demostrado que la 
deficiencia autosómica dominante en GATA2 es causada por haploinsuficiencia y su 
penetrancia clínica es incompleta. Por tanto, se debería considerar una deficiencia en GATA2 
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en pacientes de cualquier edad que presenten infecciones por micobacterias, con o sin otros 
signos relacionados con la deficiencia. Además, todos sus familiares deberían ser 
genotipados. En general, estos resultados demuestran la importancia de caracterizar 
mutaciones nuevas en genes conocidos. Aunque el gen se conozca, el impacto de la mutación 
no se puede verificar sin haberla caracterizado.
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SUMARY 
 
INTRODUCTION 
 Since the discovery of Mycobacterium tuberculosis in 1882 by Robert Koch, more 
than 150 species from the genus Mycobacterium have been described. A few of these 
mycobacteria are virulent and cause disease in many individuals. However, most 
mycobacteria are environmental mycobacteria, weakly virulent and found regularly in the 
environment. Mycobacterial diseases in human can be caused by the virulence of the 
microorganism or because the individual has an affection that renders them susceptible to the 
mycobacterial infection, known as immunodeficiencies. Immunodeficiencies can be 
secondary (also known as acquired) or primary, depending if the mycobacterial disease is an 
indirect or direct consequence of the defect. Primary immunodeficiencies underlying 
mycobacterial disease are defects within the immune system affecting the crosstalk between 
the antigen presenting cells and the lymphoid effector cells. Individuals with primary 
immunodeficiencies can suffer from a broad or a narrow spectrum of infections, both 
including mycobacterial infections. Those predisposed to narrow infections may present with 
infections by one or two microorganisms, mycobacteria being one of them. Within this latter 
category Mendelian susceptibility to mycobacterial diseases (MSMD) can be found, which 
predisposes to mycobacterial infections that may or may not be accompanied by infections 
caused by other microorganisms. 
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OBJECTIVES AND METHODOLOGY 
  Patients susceptible to mycobacterial infections, especially to weakly virulent 
mycobacteria, require a genetic diagnosis and characterization of the genetic defect in order 
to provide a customized treatment and counselling for the family. Using next generation 
sequencing and Sanger sequencing, we have identified mutations in genes associated to 
mycobacterial infections, IFNGR2 and GATA2 respectively, which we hypothesized were 
causing the disease and that we aimed to characterize. In order to prove this hypothesis, we 
used an overexpression system, immortalized cells and fresh blood from the patients to 
perform assays like electrophoretic mobility shift assays (EMSAs) or luciferase reporter 
assays that allowed us to characterize the mutations. Moreover, we used bioinformatic tools 
in order to predict in silico the consequence of the mutations found. 
 
RESULTS AND DISCUSSION 
Two novel mutations in IFNGR2 and 10 known and one novel mutation in GATA2 
were found to confer predisposition to mycobacterial diseases. For IFNGR2 three patients 
with MSMD, two individuals from Turkey and one individual from India, were studied by 
whole-exome sequencing. A homozygous mutation at the initiation codon (c.1A>G) of 
IFNGR2 in the two Turkish patients and another homozygous mutation for a frameshift 
deletion of one base pair immediately after the initiation codon (c.4delC) in the Indian patient 
were found. Given the location of these mutations, it was expected to observe an abolished 
response to IFN-γ. Through overexpression, the mutant alleles were observed to produce low 
levels of full-length IFN-γR2 and to have an impaired, but not abolished, response to IFN-γ. 
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In light of this observation, immortalized cell lines from the c.1A>G patients were studied. 
It was shown that SV40 fibroblasts from these patients responded weakly to IFN-γ, whereas 
their Epstein Barr virus transformed B cells had an almost abolished response to IFN-γ. In 
order to confirm the results observed in immortalized cell lines, studies in primary T cells 
and monocyte derived macrophages from patients with the c.1A>G mutation were 
performed. Primary cells from the c.1A>G mutation patients showed and impaired but not 
abolished response to IFN-γ, as seen for the overexpression and immortalized cell lines. 
Finally, it was observed that the residual protein expression of IFN-γR2 of normal molecular 
weight and function was due to initiation of translation between the non-AUG second and 
ninth codons within the signal peptide of the protein. The shorter signal peptide appeared to 
be sufficient for entering the secretory pathway.  
For GATA2, 14 index cases with mycobacterial disease were recruited. These patients 
carried one of a total of 11 different heterozygous GATA2 mutations, one of which had not 
been reported before. Three relatives of these index cases also had mycobacterial disease and 
were carriers for a GATA2 mutation, adding up to a total of 17 patients. The 11 mutations 
were studied in an overexpression system, where it was observed that 10 of them affected the 
correct expression of GATA2. Moreover, the characterizations of these mutations lead to the 
observation that seven mutations were loss-of-function and four hypomorphic. In addition, 
no mutation was found to be dominant-negative in vitro and, the evaluation of the GATA2 
locus showed that it evolved under purifying selection, suggesting a mechanism of 
haploinsufficiency for GATA2 deficiency. The mycobacterial infections in these patients 
were observed to be caused by different species of mycobacteria, predominantly two 
environmental mycobacteria (M. avium and M. kansasii) and M. tuberculosis. Mycobacterial 
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infection was the first clinical manifestation in 10 patients and most patients also suffered 
from other bacterial and/or fungal infections (e.g. Staphylococcus, Clostridium, 
Streptococcus, Candida, and Aspergillus). Hematological disorders such as monocytopenia, 
myelodysplasia or acute myeloid leukemia were also observed in these patients. Sixteen 
family members were shown to be carriers for a GATA2 mutation but completely 
asymptomatic, leading to the evaluation of clinical penetrance, which was found to be 
incomplete. Moreover, clinical penetrance for mycobacterial disease was found to be similar 
to other GATA2 deficiency-related manifestations. 
 
CONCLUSIONS 
 The characterization of mutations in IFNGR2 and GATA2 has allowed the treating 
and counseling of patients suffering from mycobacterial diseases. The two mutations found 
in IFNGR2 provide the first evidence of a quantitative, as opposed to qualitative, partial 
defect of IFN-γR2. Its clinical severity is intermediate between those of known complete and 
partial IFN-γR2 deficiencies. The evaluation of GATA2 mutations has shown that autosomal 
dominant GATA2 deficiency is dominant by haploinsufficiency and displays incomplete 
penetrance. For this reason, a diagnosis of GATA2 deficiency should be considered in 
patients of any age with mycobacterial infections, especially, but not exclusively, in the 
presence of other GATA2 deficiency-related phenotypes. Moreover, all direct relatives 
should be genotyped for the GATA2 locus. Overall, these results highlight the importance of 
characterizing novel mutations in known genes. Even if the gene is known, without proper 
characterization the impact of the mutation cannot be ascertained.
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INTRODUCTION 
Mycobacterial diseases are, to date, an important burden to humans and remain a 
serious and frequent challenge to health systems.1,2 Infection by M. tuberculosis, which 
causes tuberculosis (TB), is the ninth leading cause of death worldwide and the leading cause 
from a single infectious agent, ranking above Human Immunodeficiency Virus (HIV).2 
Interestingly, of the estimated 1.7 billion people infected with M. tuberculosis, only 5 to 10% 
will develop TB.2 TB burden is predominantly seen in low to middle-income countries, most 
of the current TB cases occurring in South-East Asia (45%), Africa (25%) and Western 
Pacific (17%).2 TB cases can be associated to other health factors, such as undernourishment 
(20% of TB cases), co-infection with HIV (10%), smoking (8%), diabetes (7.5%) or 
alcoholism (4.5%).2 Moreover, over the past three decades, environmental mycobacteria 
(EM), also known as nontuberculous mycobacteria (NTM), have been recognized as 
important opportunistic pathogens, causing a wide range of diseases, and whose incidence 
surpasses TB in resource-rich countries.3–6 Disease caused by EM is worsened by other health 
risks, as seen for TB.7 The virulence of the pathogen (including here its drug resistance), as 
well as the genetic background of the host, will determine the outcome of the infection in the 
affected individual.8 The genetic dissection of host predisposition to mycobacterial diseases 
provides understanding of the physiopathological mechanisms associated with anti-
mycobacterial immunity.8 The study of the immune response to mycobacteria may lead to 
the discovery of new therapeutic targets and thus overcome the resistance for the existing 
treatment. 
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I. History and pathogenicity 
1. The discovery of M. tuberculosis by Robert Koch  
The oldest evidence of mycobacterial diseases dates from a 9000-year-old settlement 
in the Eastern Mediterranean, where two individuals appeared to have suffered from TB.9–11 
Since then, from old civilizations around the world (such as ancient Egypt, pre-Columbian 
communities and Indian kingdoms) until now, mycobacterial diseases have always been 
present.11–13 However, the discovery of the pathogen responsible for TB is relatively new and 
was preluded by a series of observations and hypothesis regarding the origin of the disease. 
In the XVIIIth century, Benjamin Marten hypothesized that consumption (TB at the time) 
could be caused by “small living creatures” and that these creatures could be passed on by 
sick individuals to healthy ones.14 Jean-Antoine Villemin demonstrated in 1865 that TB was 
transmissible, after observing the high frequency of TB in soldiers in barracks compared to 
those in the field.15,16 Thanks to these discoveries, Robert Koch was able to postulate his 
hypothesis that TB was caused by “foreign parasitic structures” and isolated for the first time 
the microorganism responsible of TB. To this end, R. Koch developed a staining method that 
allowed marking the microorganism inside the tissue of individuals with TB. He then isolated 
the microorganism, which he named Tuberkelvirus and was later renamed Mycobacterium 
tuberculosis.17,18 Once isolated, he inoculated the microorganism into a healthy individual 
and observed if the same disease was developed, leading to the discovery of the causative 
agent of TB.17 The criteria followed to discover the etiology of TB were then transformed 
into what are known as Koch’s Postulates (Figure 1). Both the staining and isolation of M. 
tuberculosis were groundbreaking discoveries that would win R. Koch the Nobel Prize of 
Medicine in 1905.11,16 
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Figure 1 - Koch's postulates, criteria designed to establish a causal relationship between a causative microbe 
and a disease. Adapted from OpenStax College, Microbiology. OpenStax CNX. Under Creative Commons 
Attribution 4.0 International License. 
 
2. Mycobacteria and their pathogenicity 
 To date, there are more than 150 recognized species of the genus Mycobacterium, of 
which only a few have been reported to cause disease in humans.19 The ground breaking 
discoveries of R. Koch have allowed the better understanding of the structure, composition 
and, in the latter years, the pathogenicity of mycobacteria. All mycobacteria are aerobic, non-
spore forming, non-motile and rod-shaped. The distinctive feature of the genus, and the 
reason behind the special staining, is the lipid-rich cell envelope, which has granted them the 
name of Acid-fast bacilli (AFB) (Figure 2).20,21 Their genome plays a very important role in 
the pathogenicity of each species.22 Whole-genome analyses have revealed key differences 
between more virulent and less virulent mycobacteria, such as the coding regions and the 
size of the genome.22 
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Figure 2 – Mycobacterial cell envelope. (Adapted from Brennan & Draper. AMS; 1994:271-284)21 
 
 However, the pathogenicity of mycobacterial infections not only depends on the 
virulence of the mycobacteria but also on the immune response of the host.22 The main 
virulence factor of mycobacteria is the capacity to invade, survive and replicate within 
macrophages. Briefly, the microorganism enters the macrophage by phagocytosis and is 
surrounded by a membrane-bound vacuole that will give place to a nascent phagosome. The 
maturation of this phagosome will expose the microorganism to antimicrobial factors such 
as reactive oxygen species (ROS), hydrolytic activities and acidic pH that will destroy it. 
Virulent mycobacteria can obstruct the maturation of the phagosome, inhibit or tolerate 
acidification and can escape into the cytoplasm.22 At the same time, antigen-presenting cells 
(monocyte/macrophage lineage, APC) will engulf the mycobacteria and process the antigen 
in two different ways: the phagosome, that will allow the presentation of these antigens by 
the major histocompatibility complex (MHC) class II molecules; or the cytoplasm, that will 
lead to MHC class I molecules presentation. This process will result in secretion of 
interleukin (IL)-2 and IL-12 leading to clonal proliferation of CD4+ and CD8+ lymphocytes 
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(α/β T cells). Expanded CD4+ cells and, to a lesser extent, CD8+ cells, natural killer (NK) 
cells and γδ T cells will release interferon (IFN)-γ that will activate macrophages. This 
activation will initiate a cascade of events leading to further macrophage activation and tumor 
necrosis factor (TNF) and IL-12 production, resulting in the search, engulfment and 
destruction of mycobacteria and affected cells (Figure 3).22,23  
 
Figure 3 - Overview of the immune response in mycobacterial infection. (Adapted from Kaufmann et al. The 
Lancet; 2010: 2110-2119)23 
 
3. Treatment and vaccine 
The first available treatment for TB appeared in the XIXth century and involved a 
change of lifestyle, in which patients were invited to live at high altitudes with fresh air, mild 
exercise and repose.24 Since then, different drugs were developed that proved to have a better 
efficiency when given together, starting what was called “triple therapy” (streptomycin, para-
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aminosalicylic acid (PAS) and isoniazid).24,25 Between 1950 and 1970 new medications were 
discovered that lead to less secondary effects and that could be used against drug-resistant 
mycobacteria.26 Nowadays, treatment against any kind of mycobacteria is evaluated 
depending on the isolated microorganism, the response to the therapy, tolerance and 
adherence of the patient. More than 15 drugs have been developed for the treatment of TB, 
among which the preferred ones are rifampin, ethambutol, isoniazid and macrolides.24,27,28 
Regular treatment lasts six months, having an 85% success rate. If drug resistance is found 
the treatment can be prolonged from nine to 20 months.2 
Research for a vaccine against TB was started in 1900 by Albert Calmette and Camille 
Guérin at the Pasteur Institute in Lille.29 From 1908 to 1919, they cultivated a virulent strain 
of M. bovis which was subcultured until demonstrated to fail to produce progressive TB in 
animals. The vaccine was named Bacillus Calmette-Guérin, or BCG, in honor of the two 
researches that developed it. In 1921, the first administration of the vaccine in humans took 
place, which was given orally and, by 1931, a special laboratory was set in Paris to 
manufacture the BCG vaccine.29 Since this time, several strains of the vaccine have been 
developed from the original one of 1920, of which five are used in 90% of the cases.29–31 
Since BCG vaccination policies, practices and strains vary depending on the country a BCG 
World Atlas (http://www.bcgatlas.org) was created to access detailed information about BCG 
use worldwide.32 BCG vaccination is recommended in neonates who live in areas that have 
a high incidence of TB and has been shown to prevent childhood TB meningitis and miliary 
TB disease, providing also protection against leprosy.30 Interestingly, the BCG vaccine has 
been shown to have associated problems in some individuals, where 1 every  2,500 vaccines 
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cause localized BCG-associated complications (BCG-itis) and 1 every 100,000 vaccines 
present disseminated complications (BCG-osis).33  
4. Susceptibility to mycobacteria 
 Some individuals are prone to disease caused by mycobacteria, which is known as 
susceptibility to mycobacteria.28,34–37 It is estimated that around a third of the world’s 
population is infected with M. tuberculosis but that only 10% of this group will develop 
mycobacterial disease.2,28 EM diseases or disseminated disease caused by BCG vaccine, 
occur when the host is suffering from an immunodeficiency.28,38 Immunodeficiencies can be 
divided in two main groups: primary immunodeficiencies (PIDs), which are due to inherent 
dysfunction of the immune system and that will be addressed extensively in the next section; 
and secondary immunodeficiencies (SIDs) or acquired immunodeficiencies, which are a 
consequence of other causes.39 Among the causes for SID which lead to mycobacterial 
infection are: acquired immune deficiency syndrome (AIDS) due to HIV infection, 
immunosuppression, leukemia and immune reconstitution inflammatory syndrome 
(IRIS).28,39  
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II. PIDs 
 PIDs are a group of rare, chronic disorders whose main characteristic are intrinsic 
defects of the immune system.40,41 These defects predispose those suffering them to a variety 
of manifestations, including recurrent infections and unusual adverse reaction to vaccination. 
As of February 2017, 354 inborn errors of immunity have been reported, caused by mutations 
in 344 different genes.41  
1. The genetic approach to understanding PIDs 
 Four main factors have been claimed to play a role in the development of an infectious 
disease, explaining the clinical variability existing between patients suffering from the same 
infection. These factors are: microbial variability (microbiological theory), environmental 
variability (ecological theory), somatic immunity variability (adaptive and acquired 
immunity, immunological theory) and germline immunity variability (intrinsic, innate and 
adaptive immunity, genetic theory) (Figure 4).42 These four pillars explaining disease 
development are complementary and overlapping.42 The genetic theory appeared towards the 
second half of the XXth century in response to some gaps left by the microbiological theory 
and the immunological theory (such as vaccination failure in some individuals and 
interindividual variability in the course of a primary infection), trying to link intrinsic errors 
of the individual to the observed phenotype.42,43 This theory was properly validated with the 
discovery of three PIDs conferring predisposition to a narrow range of diseases (membrane 
attack complement defects and X-linked lymphoproliferative disease).42,44,45 From that 
moment onwards, single-gene mutations underlying susceptibility to different infections 
(such as herpes simplex encephalitis, pneumococcal disease and mycobacterial disease) were 
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identified.44,46,47 It is thanks to these major discoveries that, to this date, mutations described 
in 344 genes have explained the PIDs presented by several individuals around the world.41 
 
Figure 4 – The four complementary theories of infectious diseases. (Adapted from Casanova and Abel; Annual 
Review of Genomics and Human Genetics; 2013: 215-243)42 
 
2. Mycobacterial diseases in PIDs 
Predisposition to mycobacterial diseases in PIDs occurs as the sole infection in otherwise 
healthy individuals, or it is accompanied by a much broader susceptibility to pathogens due 
to more profound immune defects.48,49 To this end, this section has been subdivided into 
“Broad predisposition to multiple and mycobacterial infections” and “Narrow predisposition 
to mycobacterial diseases: Mendelian susceptibility to mycobacterial diseases (MSMD)”. 
a. Broad predisposition to multiple and mycobacterial infections  
 Classical PIDs are characterized by chronic or recurrent infections caused by a wide 
range of pathogens (viruses, bacteria, fungi and protozoa), among which mycobacteria are 
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included. Patients suffering from classical PIDs suffer from life-threatening diseases during 
early childhood. In this category we can find Severe Combined Immunodeficiency (SCID), 
Combined Immunodeficiency (CID), Chronic Granulomatous Disease (CGD) and syndromic 
MSMD, which includes: autosomal dominant (AD) Guanine-adenine-thymine-adenine 2 
(GATA2) deficiency, autosomal recessive (AR) Signal Transducer and Activator of 
Transcription 1 (STAT1) deficiency, AR IRF-8 deficiency, AR Retinoic acid-related orphan 
receptor gamma/gammaT (RORγ/γT) deficiency, partial AR JAK1 deficiency and AR 
Tyrosine kinase 2 (TYK2) deficiency. Affected cell types include lymphoid and myeloid 
lines. 
a.1 SCID and CID 
 SCIDs are immunodeficiencies characterized by the dysfunction of cellular and 
humoral immunity.41,50 These patients suffer from disseminated life-threatening infections 
by poorly virulent agents of viral, bacterial, fungal or parasitic origins in their first months of 
life.51–53 Mycobacterial diseases in these patients are mainly caused BCG, being mostly 
BCG-osis, even though some BCG-itis have been described.54 Infections by EM and M. 
tuberculosis have been reported but are less common, probably because the patients are not 
regularly exposed to these mycobacteria.49,54 The immunological hallmark of these 
individuals is profound T-cell lymphopenia with or without reduced numbers of circulating 
B cells, who can also present a small thymus lacking thymocytes, their spleen is deficient in 
T cell areas and formation of tonsils and lymph nodes are missing.53 In some cases, numbers 
of NK cells and myeloid cells can also be affected.55 So far, X-linked mutations in one gene 
and AR mutations in 16 genes have been described to cause SCID, the X-linked gene and 
eight autosomal genes causing profound T cell deficiency with normal B cell count56–64 and 
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eight autosomal genes causing profound T and B cell deficiency.41,65,74,66–73 Of these 17 
genes, nine genes have been linked to mycobacterial diseases, four with T cell deficiency but 
normal B cells (T-B+ deficiency, annex section I. SCID and CID causing genes, Table 1 – 
SCID causing genes) and five with both T and B cell deficiency (T-B- deficiency, annex 
section I. SCID and CID causing genes, Table 1 – SCID causing genes). BCG vaccination is 
contraindicated in SCID patients, given that any of them could develop an adverse effect to 
the vaccine.54 
 CIDs also affect cellular and humoral immunity but are generally less profound than 
SCID.41,49 CIDs can be subdivided into CID or CID with associated syndromic features, 
which present prominent characteristics not associated to the immune defect (dermatological 
and neurological defects being the most common), broadening the clinical phenotype of these 
patients.75 Patients are susceptible to poorly virulent agents of viral, bacterial, fungal or 
parasitic origins, suffering from recurrent infections that can be either localized (mostly in 
the respiratory and gastrointestinal tract) or disseminated.76 Mycobacterial infections are 
mostly disseminated and caused mainly by BCG, as the vaccine is administered within the 
first months of life, followed by EM infections and then M. tuberculosis infections.49,76 These 
types of immunodeficiencies are characterized by defective development or function of T 
cells, that maybe accompanied by B cell dysfunction and immunoglobulin defects.76 
Mutations in 102 genes have been reported to cause CID, seven of which are X-linked, 11 
have an AD mode of inheritance, three can either be AD or AR and 81 are AR.41 Only 15 of 
these genes, of which eight cause syndromic CID, have been linked to mycobacterial diseases 
(annex section I. SCID and CID causing genes, Table 2 – CID causing genes).49,77-102 The 
INTRODUCTION 
 Page 36 
  
severity of the T cell defect in these patients might determine whether the patients will suffer 
or not from mycobacterial infections.49 
a.2 CGD 
 CGD is a PID affecting the nicotinamide adenine dinucleotide phosphatase (NADPH) 
oxidase complex subunits, responsible of the respiratory burst in phagocytic leukocytes. It 
can be divided into classic CGD and p40phox deficiency. Classic CGD is the result of 
mutations in genes encoding for the NAPDH oxidase complex subunits: CYBB, encoding for 
gp91phox and the only X-linked; CYBA, encoding for p22phox; NCF1, encoding for p47phox; 
and NCF2, encoding for p67phox.49,103,104 Mutations in NCF4, encoding for p40phox, have been 
described to cause a milder form of CGD (p40phox deficiency) that do not suffer from invasive 
infections or mycobacterial disease, with the exception of one patient who also carried an 
AD STAT1 mutation.105 Briefly, the catalytic glycoprotein gp91phox will interact with p22phox 
in the cell membrane to form cytochrome b558 which will attract the cytosolic p67
phox, p47phox 
and p40phox which in turn will recruit Rac1/2. This will provoke a conformational change on 
gp91phox that will enable cytosolic NADPH to give an electron to molecular oxygen in the 
phagolysosome to form superoxide ions that will be used to generate ROS.104 Phagocytic 
cells, i.e. granulocytes, monocytes and macrophages; are the leukocytes affected by this 
disease.106 This classic CGD is characterized by life-threatening, recurrent infections 
(bacterial and fungal) and dysregulated inflammation, which can lead to autoimmunity.103,104 
Sites of infection include the lung, skin, lymph nodes and liver.103 Mycobacterial diseases, 
specifically, are usually severe and localized, being relatively common in patients living in 
endemic countries for TB, where BCG vaccine is compulsory.49,103,104,106 BCG is the most 
isolated agent in patients suffering from these type of infections, followed by M. tuberculosis. 
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EM infections have been reported in isolated cases, appearing to be rare when compared to 
BCG disease and TB, probably because NADPH is not critical in the control of these 
agents.49,106 Patients are mainly infected by pyogenic bacteria and fungi, specially 
Staphylococci and Aspergillus species.103,104 The overall estimation of mycobacterial disease 
in classic CGD patients is at 25%, sometimes being the first observed clinical 
manifestation.49,106 
 a.3 Syndromic MSMD 
 Syndromic MSMD is a combination of both mycobacterial disease and other 
infections associated with a more complex cellular phenotype than pure MSMD,107 which 
will be reviewed extensively in the next section. With the exception of  Tyrosine kinase 2 
(TYK2), the deficiencies listed here have not been linked to purely mycobacterial disease.107 
a.3.1 AD GATA2 deficiency 
 AD GATA2 deficiency (OMIM: 614172) was first described in 2011 and is caused 
by germline heterozygous mutations on the GATA2 gene.108–112 GATA2 is a two-zinc finger 
transcription factor responsible for the development and maintenance of hematopoietic stem 
cells (HSCs) and various hematopoietic progenitor cells in humans, where it is mainly 
expressed.113,114 GATA2 can either bind DNA as a monomer, a dimer or a heteromultimer.113 
It can be modified by phosphorylation, acetylation and sumoylation, being rapidly degraded 
by ubiquitination.113 GATA2 deficiency is the cause of a wide spectrum of clinical 
phenotypes, including monocytopenia with mycobacterial disease (monoMAC 
syndrome),109,115 familial myelodysplastic syndrome (MDS),108,110,116 chronic or acute 
myeloid leukemia (CML or AML),110,116 Emberger syndrome (primary lymphedema and 
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MDS),111,117,118 and, more rarely, isolated neutropenia,119 aplastic anemia,120 and isolated NK 
cell deficiency.112,121 GATA2 mutations are loss-of-function (LOF) or hypomorphic122 and 
seem to act by haploinsufficiency.108,123 GATA2 deficiency predisposes mainly to 
mycobacterial, viral and fungal infections.124 Mycobacterial infections are mainly caused by 
EM, mostly M. avium and M. kansasii, but some patients have been reported to have suffered 
from TB.125,126 Regarding BCG vaccination, information is only available for three patients, 
of which only one had a disseminated BCG infection.33 These infections are mostly 
disseminated, but in some cases can be localized. Infections by viruses occur in 
approximately two thirds of GATA2 deficient patient, mainly by human papillomavirus.125 
Patients have usually normal numbers of T cells (but they can be diminished in some cases) 
and show a progressive loss of monocytes, B cells, NK cells and dendritic cells (syndrome 
known as DCML)112, and have been shown to have elevated levels of FMS-like tyrosine 
kinase 3 ligand (FLT3L) in their plasma.113,122,126,127 The clinical features typically manifest 
in the second decade of life, but the age of onset varies from early childhood to late adulthood. 
Some mutation carriers remain asymptomatic throughout their life (the patient has the 
mutation but no clinical phenotype, presenting incomplete penetrance).127,128 In order to 
survive, these patients are advised to undergo hematopoietic stem cell transplantation 
(HSCT).113 
a.3.2 AR STAT1 deficiency 
 AR STAT1 deficiency (OMIM: 613796) is caused by bi-allelic STAT1 mutations. 
STAT1, encoded by the gene STAT1, is a critical transcription factor belonging to the 
JAK/STAT signaling pathways that is activated by IFN-mediated signals (IFN-α/β, IFN-γ, 
and IFN-λ or IL-29) and other cytokines, like IL-27.124,129 Briefly, binding of the cytokine to 
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its specific receptor will lead to the activation of the JAKs that are constitutively associated 
to the receptor. The JAKs will phosphorylate the intracellular domain of the receptors, 
creating a docking site for STAT1, which will be recruited, phosphorylated in the tyrosine at 
position 701 (Tyr701) and then released. Once released, phosphorylated STAT1 will either 
form homodimers with other phosphorylated STAT1 (known as gamma-activated factor, 
GAF) or heterodimers with STAT2 and interferon regulatory factor 9 (IRF-9) (known as 
IFN-stimulated gene factor 3, ISGF3). These dimers will then translocate into the nucleus, 
where they will bind to specific promoters like gamma-activating sequences (GAS) in case 
of GAF or to IFN-α/β sequence response elements (ISRE) in case of ISGF3. The binding will 
activate or modulate the transcription of specific target genes, like IL-12 in the case of IFN-
γ stimulation or IRF-7 in case of IFN-α/β (Figure 5).129,130 AR mutations in this gene have 
been described either as complete (caused by biallelic loss-of-expression and LOF STAT1 
alleles) or partial (caused by biallelic hypomorphic STAT1 alleles), affecting either the 
phosphorylation or DNA binding capacity of STAT1. Patients carrying these mutations 
suffer from severe or mild mycobacterial and viral diseases respectively.49,129,130 In complete 
AR STAT1 deficiency IFN-α/β, IFN-γ, IL-27 and IFN-λ signaling are abolished, accounting 
for the severe susceptibility to both virus and mycobacteria. The main causes of death in AR 
complete STAT1 deficiency are viral diseases or disseminated infection with BCG, which is 
why BCG vaccination is contraindicated in these patients.129,131 Infections with EM have also 
been reported, particularly with M. kansasii.130 HSCT is recommended in complete AR 
STAT1 deficiency.129 Patients with partial AR STAT1 deficiency, as opposed to the complete 
deficiency, have impaired but not abolished IFN-α/β, IFN-γ, IL-27 and IFN-λ signaling, 
accounting for the milder clinical phenotype, and get well with treatment.132–134 
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Figure 5 – Representation of IFN-α/β and IFN-γ signaling pathways. Image represents the two different ways 
STAT1 can be activated to give place to either antimycobacterial or antiviral immunity according to the 
stimulus. (Adapted from Boisson-Dupuis et al. In: Curr Opin Immunol. 2012: 364-378)130 
 
a.3.3 AR IRF-8 deficiency 
 AR IRF-8 deficiency (OMIM: 226990) is caused by bi-allelic IRF8 mutations. IRF-
8 plays a critical role in hematopoietic lineage determination, being essential in myeloid cell 
development, determining granulocyte versus monocyte fate.135 Moreover, it has been shown 
to play an important role in the development of plasmacytoid dendritic cells (pDCs) and type 
1 conventional dendritic cells (cDC1s), remaining highly expressed in differentiated DCs.136 
Complete AR IRF8 deficiency was first described in 2011, where the patient suffered from 
BCG-osis and oral candidiasis.137 Moreover, no monocytes or DCs could be detected in the 
blood. As a result of this absence, IL-12 production was impaired, rendering T cells anergic 
and with a very low capacity to produce IFN-γ.84 Since then, three other patients have been 
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reported to have AR IRF8 deficiency and EBV infection, but with no associated 
mycobacterial disease.138 Interestingly, these last three patients showed reduced but not 
abolished numbers of monocytes and DCs. However, they did show NK cells deficiency.139 
Differences in these cell numbers may account for the distinctive infectious phenotype of the 
patient described in 2011, rendering monocytes and dendritic cells key players in the 
immunity against mycobacteria. 
a.3.4 AR TYK2 deficiency 
 AR TYK2 deficiency (OMIM: 611521) is caused by biallelic TYK2 mutations. TYK2 
is a member of the JAK family, associated to the receptors of IL-12, IFN-α/β, IL-10, IL-6 
and IL-23.49,124,129,140,141 AR recessive TYK2 deficiency was first described in 2006 in a 
patient that displayed characteristics of hyper-IgE syndrome (HIES): atopic dermatitis, high 
IgE levels, and recurrent cutaneous staphylococcal infections. This patient also had BCG-
itis, gastroenteritis by Salmonella an several viral infections (including Herpes Simplex virus, 
HSV).142 In 2015, seven other patients with complete AR TYK2 deficiency where described 
with viral and/or mycobacterial infections but no HIES.143 Patients were shown to have 
impaired but not abolished cellular responses to IL-12 and IFN-α/β (explaining the 
mycobacterial and viral infections), IL-23 (with no mucocutaneous candidiasis), and IL-10 
(but with no overt clinical consequences).143 Between 2016 and 2018 three other patients 
have been described who did not develop mycobacterial disease.144,145 To date, 11 AR TYK2 
deficient patients have been described, nine of them suffering a complete deficiency and two 
suffering a partial deficiency. Of these 11 patients, 10 were BCG vaccinated, of whom four 
showed an adverse reaction to the vaccine. In one of these four patients, BCG-osis was the 
only disease recorded. Moreover, two other patients suffered exclusively from M. 
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tuberculosis infection (abdominal TB or miliary TB).143 Overall, three TYK2 deficient 
patients had a phenotype of pure MSMD, which will be discussed in the next section. 
a.3.5 AR RORγ/γT deficiency 
AR RORγ, and its isoform RORγT, deficiency (OMIM: 616622) is caused by bi-
allelic RORC mutations. Both RORγ and RORγT are transcription factors. RORγT, whose 
expression is restricted to leukocytes, is the most studied of both isoforms, which has been 
observed to play a role in IL-17A/F and IL-22 producing lymphocytes (including ILC3, γδ T 
cells, and Th17) cells in mice.146 Defects in IL-17A/F immunity are linked to chronic 
mucocutaneous candidiasis (CMC) but not to mycobacterial diseases.41 However, in 2015, 
AR RORγ/γT deficiency was described in seven patients suffering from both CMC and 
mycobacterial disease.147 All seven patients were BCG vaccinated and developed 
mycobacterial disease (either by BCG or M. tuberculosis).148 These patients presented T cell 
lymphopenia, small thymus, and a lack of palpable axillary and cervical lymph nodes. 
IL17A/F secretion was impaired in T cells from the patients, accounting for CMC. 
Surprisingly, IFN-γ secretion was found to be impaired in γδ T cells and Th1* cells (cells 
secreting both IL-17A/F and IFN-γ), accounting for the mycobacterial disease observed in 
these patients.  
a.3.6 Partial AR JAK1 deficiency 
 Partial AR JAK1 deficiency (OMIM: 147795) is caused by bi-allelic JAK1 mutations. 
JAK1 is a tyrosine-kinase involved in the intracellular signalization of many cytokines, 
including IFN-α/β and IFN-γ.149 It is associated to the receptors of these cytokines, allowing 
the activation of transcription factors as described in section a.3.2 AR STAT1 deficiency and 
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depicted in Figure 5. Partial AR JAK1 deficiency was described for the first time in 2016 in 
a patient who suffered from systemic atypical mycobacterial disease and who had a history 
of viral, fungal, and parasitic skin infections.150 Besides, the patient developed a mild T cell 
lymphopenia and severe anemia in his mid-teens. The mutant JAK1 was shown to be 
hypomorphic, accounting for the impaired, but not abolished, response to IFN-α, IFN-γ, IL-
27, IL-10, IL-2 and IL-4 in the patient’s lymphocytes.151 Cellular responses to IFN-γ and 
IFN-α were impaired but not abolished by this mutant allele in in primary fibroblasts and in 
overexpression system (U4A cells), where phosphorylation of STAT1 and STAT2 was 
measured. The patient also suffered from urothelial carcinoma. Overall, partial AR JAK1 
deficiency causes susceptibility to mycobacteria due to the impairment of IFN-γ signaling 
and to other infections due to the impairment of response to other cytokines including IFN-
α.151 
b. Narrow predisposition to mycobacterial diseases: MSMD 
 MSMD is a rare group of PIDs which predisposes otherwise healthy individuals to 
infection by weakly virulent mycobacteria and, in few cases, to Salmonella and Candida 
infections.35,152 Onset of the disease is usually in childhood, but it can also be observed in 
adolescence and adulthood. Clinical manifestations observed in these patients range from 
localized to disseminated, and are mostly due to EM and BCG, but some cases of infection 
by M. tuberculosis have also been described.35,152 Prevalence is 1 every 50,000 individuals 
and no overt immunological and hematological abnormalities are observed.35,153 The first 
description of MSMD was probably in 1951, in a child with disseminated disease caused by 
BCG who remained otherwise healthy.154 However, it was not until 1996 that the first genetic 
etiology for MSMD was described, when a homozygous mutation in IFNGR1 was shown to 
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be responsible for a fatal BCG disseminated disease in an otherwise healthy patient.46 Since 
then, mutations in 11 genes conferring MSMD (IL12B, IL12RB1, ISG15, TYK2, IRF8, 
SPPL2A, CYBB, IFNGR1, IFNGR2, STAT1, NEMO) have been found, whose allelic 
heterogeneity is responsible for 21 different genetic disorders.35,49,143,155 The products of 
these genes (Figure 6) either control the production (IL-12p40, IL-12Rβ1, TYK2, NEMO, 
ISG15, IRF-8 and SPPL2a) and/or the response to IFN-γ (IFN-γR1, IFN-γR2, STAT1, IRF-
8 and gp91phox).35,143,155 Interestingly, specific modes of inheritance in genes that cause 
mycobacterial disease with a broader infection phenotype (like NEMO, gp91phox, STAT1 and 
IRF-8) can also cause pure MSMD.35,49 
 
 
Figure 6 – MSMD causing genes and their cellular implication in the production or response to IFN-γ. Protein 
deficiencies that cause MSMD are depicted in blue, those responsible only for mycobacterial disease with a 
broader infection phenotype are depicted in red, and those described for both MSMD or MSMD combined with 
other infections are depicted in red and blue. (Adapted from Rosain et al. Immunology and Cell Biology; 2018; 
in press)107 
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b.1 Defects in IFN-γ production 
b.1.1 AR IL-12p40 and IL-12Rβ1 deficiencies 
IL-12, also known as IL-12p70, is a cytokine composed of the subunits IL-12p40 and 
IL-12p35.124 IL-12 signals through IL-12 receptor (IL-12R), which is formed by the subunits 
IL-12Rβ1 and IL-12Rβ2 and are associated to TYK2 and JAK2 respectively. IL-12 signaling 
will result in IFN-γ production and secretion.124 IL-12Rβ1 is encoded by IL12RB1 and IL-
12p40 is encoded by IL12B. Recessive mutations in both of these genes (either homozygous 
or compound heterozygous) give place to a complete deficiency of their encoded proteins 
that can be with or without protein expression. To date, 220 patients with AR complete IL-
12Rβ1 deficiency have been described (OMIM: 614891).129 NK cells and T cells of IL-
12Rβ1 patients have a lack of response to both IL-12 and IL-23 (IL-23 receptor is formed by 
the heterodimer of IL-12Rβ1 and IL-23R)19 that lead to low IFN-γ production. These patients 
are prone to infections by BCG, EM or M. tuberculosis, and half of them also present 
nontyphoidal salmonellosis.156 Some of the patients also show mild forms of CMC, probably 
due to the impairment of IL-23 signaling. On the other hand, AR complete IL-12p40 
deficiency (OMIM: 614890) has been reported in 50 patients who show a low production of 
IFN-γ. Infections in these patients are usually caused by BCG after vaccination, but infections 
caused by EM and M. tuberculosis have also been described. Clinical phenotype is thought 
to be mild, but it has been shown that it can range from asymptomatic to death at early 
stages.35,157 Overall, prognosis for these patients is good since recurrence of disease is rare. 
A combination of antibiotics and IFN-γ injection should suffice as treatment.129 
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b.1.2 AD IRF-8 deficiency 
 In contrast to AR IRF-8 deficiency (see section a.3.3 AR IRF-8 deficiency), AD IRF-
8 deficiency (OMIM: 614893) is caused by heterozygous mutations in IRF8, of which one 
has been shown to have a negative effect on the wild type (WT) protein (dominant 
negative).139,158 These mutations give place to an expressed hypomorphic IRF-8 protein that 
causes the diminishment of conventional dendritic cells in charge of producing IL-12 and an 
impaired production of IFN-γ by mycobacterium-specific memory Th1* cells.155 Patients 
with AD IRF-8 deficiency suffer from BCG disease, without any other infectious disease, 
unlike those who suffer from AR deficiency. Prognosis for these patients is good and 
antibiotics are the only recommended treatment.124,129  
b.1.3 AR SPPL2a deficiency 
 In 2018 one new genetic etiology of MSMD has been described. Homozygous 
mutations in signal peptide peptidase-like 2A (SPPL2A) gene, encoding for SPPL2a, were 
described in three patients suffering from BCG disease after vaccination.155 SPPL2a is a 
protease in charge of degrading the amino-terminal fragment of the human leukocyte antigen 
(HLA) invariant chain (CD74) of antigen-presenting cells.  If this fragment is not degraded 
it accumulates in the cells, having a toxic effect on them. SPPL2a deficient patients have 
been shown to have a selective depletion of IL-12 and IL-23-producing CD1c+ conventional 
type 2 dendritic cells (cDC2s) and their circulating progenitors. Moreover, Th1* cells have 
been shown to have an impaired IFN-γ production after stimulation with mycobacterial 
antigens. These results have been corroborated in Sppl2a deficient mice, which were 
susceptible to mycobacterial diseases. Overall, SPPL2a deficiency causes MSMD through a 
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quantitative defect of IL-12 and IL-23-producing cDC2s and through an impaired production 
of IFN-γ by mycobacterium-specific memory Th1* cells. These patients have been found to 
be similar to AD IRF-8 deficient patients, and their prognosis seem to be the same.155 
b.1.4 AR ISG15 deficiency 
 Interferon-stimulated gene 15 (ISG15), encoded by ISG15, is a ubiquitin-like protein 
that attaches to substrates in a process called ISGylation, which is similar to ubiquitination.159 
ISG15 can be secreted by neutrophils, monocytes and lymphocytes and induces potently IFN-
γ production in lymphocytes when synergized with IL-12. Since its discovery in 2012, 
complete AR ISG15 deficiency (OMIM: 616126) has been described in six patients with loss 
of expression and function mutations.160,161 The common clinical feature of these patients 
was calcification of the basal ganglia in the brain. Of these six patients, three developed 
mycobacterial disease due to BCG vaccination. T and NK cells of the patients displayed an 
impairment, but not abolishment, of IFN-γ production after stimulation with BCG and IL-
12.160 Addition of recombinant ISG15 rescued the IFN-γ production in both T and NK cells 
of the patients. Interestingly, calcification in the brain can be explained by and enhanced 
IFN-α/β activity, which is caused by the destabilization of USP18, a negative regulator of 
this cytokine.162  
b.1.5 X-linked recessive NEMO deficiency 
 NEMO or IKBKG encodes for inhibitor of nuclear factor kappa-B kinase subunit γ 
(IKKγ) or nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) essential 
modulator (NEMO). This gene plays a role in NF-κB signaling.124. Regarding its function, 
NF-κB is a transcription factor conformed by either homo or hetero-dimers of five different 
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proteins in the Rel family (p50, p52, RelA, c-Rel and RelB). At the steady state, NF-κB is 
inhibited by IkBα, IkBβ and IkBε. When the cell is stimulated, IKKs complex (IKKα, IKKβ 
and the regulatory subunit IKKγ) will phosphorylate the IkBs allowing NF-κB’s 
translocation to the nucleus and the transcription of several immune system receptors and 
receptors of ectodermal and bone cells.124 X-linked recessive NEMO deficiency is linked to 
a syndromic CID called anhidrotic ectodermal dysplasia with immune deficiency (EDA-ID, 
OMIM: 300291).101,102 However, 11 patients suffering from X-linked recessive NEMO 
deficiency have been reported with purely mycobacterial diseases (OMIM: 300636). These 
patients carry very specific mutations (p.E315A, p.R319Q, c.1-16G>C and c.1-16+1G>T), 
responsible for their narrow phenotype.107 These mutations are located in the region of 
NEMO that encodes for the leucine zipper domain that forms a salt bridge, which is 
fundamental in CD40-triggered IL-12 production through c-Rel.35 Cellular phenotypes of the 
patients present low IFN-γ and IL-12 production after T cell specific stimulation.163 Patients 
with this specific NEMO deficiency suffered from purely mycobacterial infections by EM, 
BCG and TB.35,129 The prognosis of the patients is variable but they can, however, benefit 
from antibiotic treatment and IFN-γ injection.35,49 
b.2 Defects in IFN-γ response 
b.2.1 IFN-γ receptor deficiencies 
 IFN-γ receptor (IFN-γR) is a heterodimer composed of two subunits, IFN-γR1 and 
IFN-γR2, encoded respectively by IFNGR1 and IFNGR2. IFN-γR1 is the ligand binding 
chain of the receptor and is associated to JAK1, whereas IFN-γR2 is the signal transducing 
chain and is associated to JAK2.149 IFN-γ stimulation will result in the dimerization of these 
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two receptors, which will activate JAK1 and JAK2 that will then phosphorylate STAT1, 
initiating the transcription of target genes (Figure 5).164 Three types of deficiencies for these 
two molecules have been described: AR complete deficiency (for IFN-γR1 OMIM: 209950; 
for IFN-γR2 OMIM: 614889), caused by bi-allelic null mutations (with or without protein 
expression) resulting in abolished IFN-γ response; AR partial deficiency, caused by bi-allelic 
hypomorphic mutations which lead to impaired response to IFN-γ; and AD partial deficiency 
(for IFN-γR1 OMIM: 615978), caused by mono-allelic mutations impairing IFN-γ signaling 
by either negative dominance (IFN-γR1) or haploinsufficiency (IFN-γR2).129 Mutations in 
IFNGR1 have been reported in more than 100 individuals, whereas mutations in IFNGR2 
have only been reported in 24.35,129,165 AR complete deficient patients suffer from severe life-
threatening mycobacterial infections, mostly EM and BCG, in early childhood and present 
high levels of IFN-γ in plasma.35,129 Viral infections have been reported in few cases.129 
Prognosis for these patients is very poor and HSCT is recommended once the mycobacterial 
disease has been controlled.129 AR partial deficient patients, as opposed to complete 
deficiency, present a less severe clinical phenotype with EM and BCG diseases mostly, with 
other bacterial diseases being reported in some cases. High IFN-γ levels in plasma may also 
be detected in these patients. Prognosis is relatively good in most cases, with antibiotic 
treatment and recombinant IFN-γ injections.129 Interestingly, one AR complete IFNGR2 
mutation (p.T168N) and AR partial IFN-γR2 deficiency have been shown to be caused by 
mutations that lead to high levels of N-glycosylation of the protein and lead to retention in 
the endoplasmic reticulum (ER).166 AD partial deficiency has been mostly described for IFN-
γR1 since, to date, AD partial IFN-γR2 deficiency has only been reported in one patient.167,168 
AD partial deficiency predisposes to EM, TB and BCG infections, mostly affecting the bones 
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(osteomyelitis). Prognosis is relatively good, with antibiotic treatment and recombinant IFN-
γ injection.129 Of note, AD partial IFN-γR2 deficiency has been shown to have incomplete 
penetrance, since only one heterozygous individual has developed mycobacterial 
disease.129,167 
b.2.2 AD STAT1 deficiency 
 In contrast with AR STAT1 deficiency (reviewed in section a.3.2 AR STAT1 
deficiency), LOF AD STAT1 deficiency (OMIM: 614892) has been purely linked to 
mycobacterial diseases.129 Mutations causing this deficiency have been shown to reduce the 
cellular response to IFN-γ but not to IFN-α, explaining the pure mycobacterial disease, and 
can either affect the phosphorylation, DNA binding capacity of STAT1 or both.129 
Mycobacterial infections in these patients can be either local or disseminated and be caused 
by EM, BCG or TB. Osteomyelitis in these patients is frequent, similar to what is observed 
in AD partial IFN-γR1 patients.129 Interestingly, some mutation carriers have remained 
asymptomatic, presenting therefore incomplete penetrance. Prognosis and treatment are 
similar to those for AD partial IFN-γR1 patients.129 
b.2.3 X-linked recessive gp91phox deficiency 
 CGD causing gp91phox deficiency has been reviewed in section a.2 . Two specific 
mutations in CYBB (p.Q231P and p.T178P) have been shown to predispose patients who 
carry them to only mycobacterial diseases (BCG-osis, BCG-itis or TB) (OMIM: 300645).35 
Interestingly, it was observed that ROS production was only abolished in monocyte-derived 
macrophages (MDMs) and Epstein-Barr Virus-Transformed B (EBV-B) cells, when 
activated with BCG and IFN-γ. Moreover, mutated gp91phox expression in these cells was 
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shown to be impaired. In contrast to CGD, where all phagocytic cells are affected, 
neutrophils, monocytes and monocyte-derived dendritic cells (MDDCs) showed normal ROS 
production after stimulation in these patients. These results highlighted the importance ROS 
production in macrophage against mycobacterial infection, whereas ROS production by 
granulocytes and monocytes is more important against fungi and pyogenic bacteria.35 
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III. Study strategy 
 The genetic diagnosis of patients with mycobacterial diseases can follow two 
strategies: immunological approach or genomic approach.  
The immunological approach consists on clinical suspicion, standardized functional 
tests and Sanger sequencing of a candidate gene (a known gene to cause mycobacterial 
disease). Clinical suspicion is based on the distinctive clinical phenotype that is displayed by 
patients who are mutated in certain genes. The clinical suspicion is strengthened by the 
functional standardized tests. These tests include the evaluation of the IFN-γ axis, which is 
the gold procedure for MSMD diagnosis. This assay was developed by Feinberg et al, 153,169 
and consists in the measurement of different cytokines (IL-12p40, IL-12p70 and IFN-γ) by 
enzyme linked immunosorbent assay (ELISA) after whole blood or peripheral blood 
mononuclear cells (PBMCs) activation. This activation is performed with live BCG with or 
without recombinant IL-12p70 or recombinant IFN-γ for 48 hours. Levels of the produced 
cytokines after these stimulations can point towards an IFN-γ production or response defect. 
Further studies can be performed, like measurement of IFN-γ levels in patients’ plasma 
(useful to determine AR IFN-γR deficiencies);153,170 evaluation by flow cytometry of receptor 
expression (like IL-12Rβ1 or IFN-γR1) to determine whether the proteins are being 
expressed or not;153 and cytometric evaluation of downstream signaling (such as STAT1 for 
IFN-γ and STAT4 for IL-12) that allows to detect defects of phosphorylation.153 The results 
obtained in these functional tests may point towards a candidate gene that can be Sanger 
sequenced in the search of a reported or novel mutation. 
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 The genomic approach consists on the use of next generation sequencing (NGS) to 
identify the gene responsible for the disease.171 This method is used for those patients that, 
despite their clear clinical phenotype, are not mutated in any of the known genes to cause 
mycobacterial disease. The working hypothesis is that there are novel mutations in 
undescribed genes that may affect, or not, the IFN-γ axis and that are mycobacterial disease 
causing.
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JUSTIFICATION, HYPOTHESIS AND OBJECTIVES 
 Since the discovery of the first genetic etiology of MSMD in 1996, 501 individuals 
with mycobacterial disease have been genetically diagnosed in the Laboratory of Human 
Genetics of Infectious Diseases. However, the genetic etiology of approximately 500 other 
patients suffering from mycobacterial diseases is still unknown. Mutations in known MSMD 
causing genes require characterization in order to discern the severity of the genetic defect 
encountered. The genetic diagnosis and functional characterization of the mutation of the 
candidate gene are key in providing a proper treatment and genetic counseling for the family, 
as well as identifying a good donor in case HSCT is required. This thesis is focused on the 
characterization of novel mutations in IFNGR2 and known and novel mutations in GATA2 in 
patients suffering from mycobacterial diseases. We hypothesize that these mutations impair 
the function of the IFN-γR2 and GATA2 proteins respectively, and are responsible for the 
mycobacterial disease in these patients. 
Specific objectives were set with the aim of proving this hypothesis: 
1. To characterize the novel IFNGR2 mutations by overexpression and in 
patients’ cells in order to determine whether they confer a complete or partial 
IFN-γR2 deficiency. 
2. To characterize in detail at the molecular, cellular, immunological, and 
clinical levels patients with GATA2 mutations and mycobacterial disease; a 
study that is lacking in the current literature.
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MATERIALS AND METHODS 
Patients and kindreds 
Patients were referred to the Laboratory of Human Genetics of Infectious Diseases in 
France due to mycobacterial infectious and hematological abnormalities. The parents and/or 
patients, as requested and approved by the institutional review boards (IRB) of the various 
institutions involved, signed an informed consent form. The experiments described here were 
performed in France, in accordance with local regulations, and with the approval of the IRB 
of Necker Hospital for Sick Children, France. Particularly for the patients diagnosed with 
GATA2 deficiency, the physicians in charge completed a detailed questionnaire including 
date of birth, date of first clinical manifestations, BCG vaccination, infectious diseases (in 
particular mycobacteria), hematological disorders, HSCT, living status and, if dead, cause of 
death. The data were collected from 2011 to 2018 and sent to the laboratory. Our analysis 
focused mainly on mycobacterial infectious disease in GATA2 patients. We did not consider 
clinical signs for other infectious diseases for the recruitment of these patients.  
Mycobacterial infection diagnosis 
Mycobacterial infectious disease was diagnosed based on clinical and radiologic 
features, staining for acid-fast bacilli (AFB), molecular PCR and/or microbiological culture 
results when available. Recurrence was defined as a subsequent episode of mycobacterial 
disease with the same microbe after a period free from clinical disease and treatment. 
Diagnosis of EM has been categorized in lung disease, according to the criteria of the 
American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA), and extra-
pulmonary disease, referred as skin and soft tissue, lymph node, bone and joint, disseminated 
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or catheter-related infections.172,173 Tuberculosis was diagnosed according to the criteria 
proposed by S. Graham et al.174 Diagnosis of confirmed tuberculosis was defined with the 
presence of at least one sign or symptom of tuberculosis with positive culture for M. 
tuberculosis. Probable infection by tuberculosis was defined by if the patient had one sign or 
symptom suggestive of tuberculosis, a chest radiography consistent with intrathoracic 
tuberculosis and at least one of the following: i) positive clinical response to anti-tuberculosis 
treatment, ii) documented exposure or close contact with a patient with tuberculosis, or iii) 
immunological evidence of M. tuberculosis by a positive tuberculin skin test (TST) or 
interferon- release assay (IGRA). Possible tuberculosis was defined by, in addition to signs 
or symptoms suggestive of tuberculosis infection, if the patient had: i) chest radiography not 
consistent with pulmonary tuberculosis but he has at least a positive clinical response to anti-
tuberculosis treatment; or documented exposure or close contact with a patient with 
tuberculosis, or immunological evidence of M. tuberculosis by TST or IGRA. 
Extraction of DNA and WES 
Genomic DNA (gDNA) was extracted from whole blood from healthy controls, the 
patients and family members, using the iPrep PureLink gDNA Blood kit and the iPrep 
instruments from Thermo Fisher Scientific. For one patient genomic DNA was extracted 
from plasma with the QIAmp DNA Blood Mini Kit (Qiagen, 51104). WES was performed 
with 3 µg of DNA. Exome capture was performed with the SureSelect Human All Exon 72 
Mb kit (Agilent Technologies, Santa Clara, CA, USA). Paired-end sequencing was 
performed on a HiSeq 2000 (Illumina, San Diego, CA, USA), generating 100-base reads. 
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The sequences were aligned with the GRCh37 reference built of the human genome, using 
the Burrows-Wheeler aligner (BWA).  
Polymerase chain reaction (PCR) and sequencing 
IFNGR2 and GATA2 were sequenced using designed primers flanking each of their 
exons and part of their intronic borders. Additionally, intron 5 of GATA2 was also sequenced 
in search of intronic regulating variants. PCRs were carried out using FastStart™ Taq 
(Roche) and a GeneAmp PCR system 9700 (Applied Biosystems). PCR products were then 
analyzed by electrophoresis in 1% agarose gels, purified by centrifugation through Sephadex 
G-50 Superfine resin (GE Healthcare) and sequenced with the Big Dye Terminator cycle 
sequencing kit (Applied Biosystems). Sequencing products were purified by centrifugation 
through Sephadex G-50 Superfine resin, and sequences were analyzed with an ABI Prism 
3700 apparatus (Applied Biosystems). The sequences were aligned to the genomic sequence 
of IFNGR2 (NM_005534.3) or GATA2 (NM_032638.4) with Genalys, version 2.0 β 
software. 
Cell culture and stimulation 
EBV-B cells, primary human fibroblasts immortalized with SV-40 T antigen (SV-40 
fibroblasts) and human embryonic kidney (HEK)293-T cells were cultured in Roswell Park 
Memorial Institute medium (RPMI, Gibco) or Dulbecco's Modified Eagle's Medium 
(DMEM, Gibco) with 10% fetal bovine serum (FBS, Gibco), referred as complete 
medium.175,176 EBV-B cells and SV40-fibroblasts were stimulated with the indicated doses 
of IFN-γ (Imukin, Boehringer Ingelheim) and IFN-α2b (IntronA, Schering Plough) for 20 
minutes. 
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Expression plasmids and cell transfection 
WT IFNGR2 allele was inserted into the V5-topo-pcDNA3.1 (Invitrogen) according 
to the manufacturer’s instructions and an insert-less V5-topo-pcDNA3.1 plasmid was kept 
as an empty plasmid (EV). GATA2-WT isoform 1 (RC208554) and GATA2-WT isoform 2 
(RC227514) in a PCMV6 backbone were bought from Origene, as well as the insert-less 
backbone. Plasmids were transformed into TOP 10 competent cells (Invitrogen). Multiplied 
plasmid extraction was performed using HiSpeed Plasmid Maxi Kit (Qiagen). Mutations in 
all the plasmids were generated by site-directed mutagenesis (PfuUltra II Fusion HS DNA 
polymerase or QuickChange II XL Site-Directed Mutagenesis Kit, both from Agilent) 
according to the manufacturer’s instructions, followed by DpnI digestion (New England 
Biolabs). HEK293-T cells were transfected with one of the various IFNGR2 V5-tagged 
pcDNA3.1 plasmids or GATA2 PCMV6 plasmids using either X-treme GENE9 transfection 
reagent (Sigma Aldrich) or Lipofectamine transfection kit (LTX and PLUS reagent, 
Invitrogen), according to the manufacturer’s instructions. IFN-γR2 deficient fibroblasts177 
and IFN-γR2 patient’s fibroblasts were also transfected with IFNGR2 V5-tagged pcDNA3.1 
plasmids. Cells were plated at 0.6x106 in six well plates and grown in 2 ml of complete 
DMEM and incubated at 37˚C in 5% CO2. After 24 hours, transfection was carried out. After 
48 hours, the cells were collected and proteins were extracted. 
Cell lysis, immunoblotting and immunoprecipitation 
Total proteins were solubilized in extraction buffer (25 mM Tris-HCl, pH 7.6, 150 
mM NaCl2, 1% NP-40, 1 mM EDTA, 1× proteinase inhibitor cocktail mix, 1 mM PMSF, and 
1 mM Na3VO4). Their concentration was then measured by the Bradford method and they 
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were incubated with Laemmli buffer 1x and NuPage (Invitrogen) as a reducing agent. 
Samples were then loaded into SDS-PAGE, 10% polyacrylamide gels (Bio-Rad) and then 
transferred into low fluorescence or normal PVDF membranes or nitrocellulose membranes 
(Bio-Rad) with the Trans-Blot Turbo Transfer System (Bio-Rad) or iBlot system 
(Invitrogen). Immunoblotting was performed using antibodies against: anti-IFN-γRβ (sc-
377291, Santa Cruz Biotechnology, Inc.), anti-V5 tag (Thermo Fisher Scientific), anti-
GATA2 antibody (sc-267, Santa Cruz Biotechnology, Inc.), anti-DDK antibody (TA5001, 
Origene) GAPDH (14C10, Cell Signaling Technology), pY701 STAT1 (612133, BD 
Biosciences), STAT1 (610116, BD Biosciences) or α-tubulin (sc-23948, Santa Cruz 
Biotechnology, Inc.). We detected bound antibody with ECL western blotting detection 
reagents (Bio-Rad) on Chemidoc or with fluorescence detector LI-COR Clx machine.  
V5 tagged IFNGR2 transfected HEK293-T cells were lysed and immunoprecipitated 
using anti-V5 tag antibody and agarose A/G beads (Santa Cruz Biotechnology, Inc.) after a 
background-clearing step with an isotype control and agarose A/G beads (Santa Cruz 
Biotechnology, Inc.). Immunoprecipitated proteins were subsequently resolved on SDS-
PAGE. Blots were either probed with anti-IFN-γRβ or the SDS gel was incubated with 
Coomasie.  
Electrophoretic mobility shift assay (EMSA) and luciferase reporter assays 
SV40 fibroblasts or EBV-B cells were stimulated for 20 min with IFN-γ or IFN- at 
the indicated doses. A two-step protein extraction was performed to separate the cytoplasmic 
and nuclear content of the cells; cells were first mixed with a membrane lysis buffer (10 mM 
Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.05 % NP40, 25 mM NaF 
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supplemented with 1 mM PMSF, 1 mM DTT, 10 µg/ml leupeptin, 10 µg/ml aprotinin) and 
incubated for 30 min on ice. The lysate was centrifuged and the supernatant was discarded. 
The remaining pellet, nuclear fraction, was mixed with nuclear lysis buffer (20 mM Hepes 
pH 7.9, 0.4 M NaCl, 1,mM EDTA, 1, mM EGTA, 25% glycerol supplemented with 1 mM 
PMSF, 1 mM DTT, 10 µg/ml leupeptin, 10 µg/ml aprotinin) and incubated for 30 min on ice. 
Five to 10 µg of nuclear extract was incubated with 32P-labeled (-dATP) or IRDye 700 GAS 
probe, corresponding to the Fc-γR1 promoter, and subjected the mixture to electrophoresis 
in a polyacrylamide gel. 
Luciferase reporter assays were performed in HEK293-T cells. 3x106 cells were 
plated in 96 wells culture plates in 100 µl of complete DMEM and incubated at 37˚C and 5% 
CO2. Lipofectamine kit was used for the transfection with various plasmids: EV, GATA2-
WT and mutated isoform 1. After 24 hours, the supernatant was discarded and luciferase 
activity was measured with the Dual-Luciferase Reporter Assay kit (Promega) following the 
manufacturer’s instructions. Other plasmids used in the experiment were PML (RC220236, 
Origene), GATA2 Luciferase reporter plasmid (LR0030, Panomics) and Renilla pRL-SV40-
d238 created by Ho and Strauss.178 Samples were read using a Luminometer (Victor X4 
model 2030, PerkinElmer). 
Flow cytometry 
Briefly, 5 x 105 SV-40 fibroblasts were incubated with 10 and 103 IU/ml of IFN-γ for 
48 h. Cells were washed with staining buffer (1X Phosphate-buffered saline or PBS, 2 mM 
ethylenediaminetetraacetic acid or EDTA, and 2% FBS) and HLA-DR levels on the cell 
surface were then evaluated by flow cytometry with an anti-human HLA-DR FITC antibody 
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(556643, BD Biosciences). STAT1 phosphorylation was assessed by activating EBV-B cells, 
previously stained with Aqua Dead Cell Stain kit (Thermo Fisher Scientific), with 105 IU/ml 
of IFN-γ or IFN-α for 30 min, washing them in cold PBS 1X, following nuclear 
permeabilization by BD phosflow buffers. Cells were then washed and incubated for 1 h at 
4ºC with either an antibody against phosphorylated STAT1 (612597, BD Biosciences) or 
with the corresponding isotype antibody (565357, BD Biosciences). Cells were washed three 
times, samples were acquired on a Gallios (Beckman Coulter), using FlowJo as the analysis 
software. 
Whole blood assay of the IFN-γ circuit and ELISA 
Heparin-treated blood samples from healthy controls, patients and parents were 
stimulated in vitro with BCG alone or with BCG plus IFN-γ or IL-12 (R&D), as previously 
described.153,169 Supernatants were collected after 48 h of stimulation and ELISA were 
performed with specific antibodies directed against IFN-γ, IL-12p70, or IL-12p40, using the 
human Quantikine HS kits for IL-12p70 and IL-12p40 (R&D Systems) and the human 
Pelipair IFN-γ (Sanquin), according to the manufacturer’s instructions. ELISA was also 
performed on plasma from GATA2 patients, their family members (when available) and 
healthy donors for human FLT3L (R&D Systems) and human macrophage colony-
stimulating factor (M-CSF) (R&D Systems) following the manufacturer’s instructions. 
Differentiation of MDMs and CD4+ T cells 
 CD14+ monocytes from PBMCs were isolated using a positive selection kit from 
Miltenyi Biotec. Briefly, 0.5 million monocytes were incubated in 6-well plates with 50 
ng/ml M-CSF (216-MC, R&D systems) and 50 ng/ml IL-4 (204-IL, R&D systems), to induce 
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MDMs differentiation during 14 days.179 CD4+ naive T cells were obtained using human 
naive CD4+ T cell isolation kit II (Miltenyi Biotec). The cells were stimulated with 105 IU/ml 
of IFN-γ or IFN-α. 
PBMCs and ribonucleic acid (RNA) analysis 
PBMCs were obtained from heparin-treated whole blood from patients and healthy 
controls by centrifugal separation through a Ficoll gradient and washing with RPMI. 
Different PBMCs populations (CD3+, CD56+, CD19+, CD14+, dendritic cells, myeloid 
dendritic cells and plasmacytoid dendritic cells) were obtained from buffy coat from healthy 
donors through Ficoll gradient and then separated by positive or negative selection with 
MACS Miltenyi beads and columns following the manufacturer’s instructions. Isolated 
peripheral blood CD34+ cells were bought from STEMCELL technologies (# 70040). Total 
RNA was extracted from different peripheral myeloid and lymphoid cells, from frozen vials 
of PBMCs from patients and healthy donors using the RNeasy Micro Kit (Qiagen). 
Retrotranscription was carried out with SuperScript II Reverse Transcriptase (Invitrogen). 
Quantitative real-time PCR (qPCR) was performed in the ABI Prism 7500 (Applied 
Biosystems) using SYBR Green master mix (Biorad) with specific primers for GATA2. 
GAPDH expression was used as an internal control. Data were analyzed using the 
comparative cycle threshold (ΔCt) method. 
Statistical analysis 
Statistical analysis was performed for the luciferase assay experiments using 
GraphPad Prism version 5.03. After checking whether the data were normally distributed, an 
unpaired t-test (Wilcoxon matched-pairs signed rank test) was used for statistical analysis, as 
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at all times two sets were compared: WT versus mutants, combinations of WT and EV versus 
combinations of WT and mutant, or WT versus combination of WT and mutant. Data were 
considered significant when p<0.01. 
Penetrance calculation 
We estimated the penetrance as a function of age for all type of GATA2-related 
disease and according to disease type (mycobacterial infection and other disease) in GATA2-
deficient first degree relatives of index cases using the non-parametric cumulative incidence 
function taking into account competing risks, as implemented in the R package “cmprsk”. 
Confidence intervals (CIs) were computed using log-log transformation to ensure that the 
lower limits of the 95% CIs were positive. 
Selective pressure measures 
Three different methods to analyze selective pressure were used to study the purifying 
selection of GATA2.180–182 Further information can be found in Annex section: II. Selective 
pressure measures.
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RESULTS 
Chapter I – IFN-γR2 deficiency  
Description of three MSMD patients 
We investigated three MSMD patients from two unrelated kindreds (Figure 7A). P1 
and P2 were born to consanguineous parents in Turkey and P3 was born to consanguineous 
parents in India.  
P1 (Kindred A, II.1, Figure 7A) was born in 2009 from a Turkish consanguineous 
family. He was BCG vaccinated at 2 months of age. At 9 months of age, he developed a local 
lymphadenitis (BCG-itis) which was apparently resolved by antibiotics but he had a relapse 
at 18 months of age. At the age of 5 years, he developed multiple cervical 
lymphadenopathies, deep neck abscesses, cervical bone lesions affecting movement of the 
neck. Salmonella serology was positive but it was not found in blood culture. At the age of 7 
years, he was admitted to the hospital for osteomyelitis in cervix, thorax, lumbar spine and 
sacral bones. M. bovis-BCG was characterized as the responsible microorganism. Subsets of 
T, B and NK cells were normal, as well dihydrorhodamine (DHR) assay on neutrophils for 
respiratory burst evaluation after phorbol myristate acetate (PMA) activation. Diagnosis of 
MSMD was suspected. He received multiple antibiotics and subcutaneous IFN-γ as treatment 
and he proved clinical improvement. He is currently 9 years-old and healthy. 
P2 (Kindred A, II.2, Figure 7A) was born in 2012 and she is the sister of P1. She 
received BCG vaccination at 2 months of age and developed suppurative lymphadenitis 
related to the vaccine that drained spontaneously. She was treated with multiple antibiotics 
and subcutaneous IFN-γ. No other infectious diseases have been detected in this patient. 
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Laboratory investigations showed a normal immunophenotyping of T, B and NK cells 
according to the age; respiratory burst was evaluated by DHR assay, being normal on 
neutrophils after PMA activation. IgG, IgA and IgM serum levels were normal for the age of 
the patient. She is 6 years-old and she is well, without any treatment. 
P3 (Kindred B, II.4, Figure 7A) was born in 2011 from Indian non consanguineous 
parents. He received BCG vaccine at 10 days of life. At 3 months he developed swelling of 
the left axillary lymph node which was drained. Histopathology showed reactive follicular 
hyperplasia with no granulomas, but AFB smear was positive. Treatment history at that point 
was not available. At 11 months P3 showed inguinal and axillary lymphadenitis and 
hepatosplenomegaly. Chest X-ray showed persistent right middle lobe patch. Gastric AFB 
was positive; mycobacterial culture was negative. Fine needle aspiration cytology from 
inguinal nodes revealed ill-defined granulomas with AFB. Mycobacterial culture from lymph 
node yielded EM, which was identified as M. chelonei. Started treatment with Rifampicin, 
Ethambutol, Clarithromycin and Aminoglycoside. IFN-γ could not be procured and parents 
were unaffordable for stem cell transplantation. He died at 5 years old of age with persistent 
disseminated EM disease. He had one elder brother who died of possible tuberculosis. His 
sister is clinically well. 
Identification of novel IFNGR2 mutations 
WES was carried out on the patients’ gDNA. We searched for rare variations (minor 
allele frequency, MAF < 0.01) in known MSMD-causing genes. In kindred A (P1 and P2), 
we found a homozygous nucleotide substitution at position c.1A>G of IFNGR2 (Figure 7B), 
which leads to the replacement of the first methionine-encoding codon by a valine-encoding 
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codon. In kindred B (P3), we identified a homozygous nucleotide deletion, c.4delC (Figure 
7B), which is predicted in silico to cause a premature stop codon 22 amino acids after the 
first methionine (M1). Both parents of the patients were heterozygous for the corresponding 
mutations (Figure 7B). We mined public databases (GnomAD, ExAC and BRAVO) and 
found that mutation c.1A>G was reported in heterozygosity in one European individual in 
GnomAD (out of 14,324 individuals, of which 7,150 individuals were European), whereas 
mutation c.4delC was not reported. Both the M1 residue (c.1ATG) and the arginine that 
follows (R2, c.4CGA) are highly conserved in the species for which IFNGR2 was sequenced 
(Figure 8A). These mutations had a high combined annotation dependent depletion (CADD) 
score,183 higher than the mutation significance cutoff (MSC) of IFNGR2184 and similar to 
other IFN-γR2 reported patients (Figure 8B). All mutations were confirmed by Sanger 
sequencing. No DNA sample was available from the siblings of P3. These mutations thus 
probably underlie AR MSMD by IFN-γR2 deficiency, whether complete or partial. 
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Figure 7 - Identification of 3 new patients with IFN-γR2 deficiency and MSMD. (A) Familial segregation of 
the c.1A>G and c.4delC mutations (mutations marked in red). Each kindred is designated by a capital letter (A-
B), each generation by a roman numeral (I-II), and each individual by an Arabic number. Healthy individuals 
are shown in white. Solid black shapes indicate patients with MSMD. The probands are indicated by arrows. 
E? stands for not genotyped. (B) Electropherogram showing the ATG-GTG mutation in P1 and P2, and the 
CGA-GA mutation in P3. (Adapted from Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
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Figure 8 - Consequences of the aminoacid alteration. (A) First 18 aminoacids of IFN-γR2 in different species 
showing conservation of the first methionine and the second arginine, indicated by arrows and in red. (B) CADD 
score of the published IFNGR2 mutations, the reported homozygous variations in public databases and of the 
mutations c.1A>G and c.4delC. (Adapted from Oleaga-Quintas et al. Human Molecular Genetics; 2018; in 
press)185 
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Expression evaluation of mutated IFN-γR2 proteins 
 We first characterized the c.1A>G and c.4delC alleles in vitro by overexpressing the 
corresponding cDNAs in HEK293-T cells or IFN-γR2-deficient SV40-fibroblasts177 
(homozygous for the c.278delAG mutation). We either left cells untransfected (NT) or 
transiently transfected cells with WT, c.1A>G, and c.4delC IFNGR2 cDNAs, or with EV, 
and analyzed the corresponding products by Western blotting.177 IFNGR2 c.278delAG, 
which is a reported loss-of-expression and LOF mutation, was included as a negative 
control.177 As expected, the WT-IFNGR2 plasmid encoded a single full-length 70-kDa 
protein; the negative control and EV showed no protein expression (Figure 9). Interestingly, 
both mutants c.1A>G and c.4delC also showed a single full-length 70-kDa protein, albeit of 
lower amounts than WT (Figure 9A). IFN-γR2 belongs to the type I transmembrane proteins 
and its glycosylation is an important post-translational modification.186 Glycosylation 
ensures correct folding of the protein and proper ligand binding to it, being also responsible 
for the range of molecular weight (MW) of this and other membrane proteins.187 The lysates 
from transient transfections of WT, c.1A>G, c.4delC, and c.278delAG were treated with 
peptide N-glycosidase-F (PNGase-F) to remove N-glycans.188 The same expression pattern 
was observed, with c.1A>G and c.4delC displaying products of equal MW (approximately 
45kDa) but lower amounts than WT (Figure 9B). These findings suggested that although one 
mutation affects the first methionine and another creates an upstream frameshift, there seems 
to be proper translation of the encoded mRNAs, ensuring the expression of a seemingly full-
length protein. These findings also confirmed that the two mutations were pathogenic and 
the patients had AR IFN-γR2 deficiency, whether complete or partial. 
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Figure 9 - IFN-γR2 protein expression. (A) HEK 293-T cells or IFN-γR2 deficient SV40-fibroblasts (IFN-γR2-
/- SV40F) were left NT or were transiently transfected with EV, WT, c.1A>G, c.4delC and c.278delAG IFNGR2 
plasmids. Total lysis and western blot were performed with anti-V5 antibody and used GAPDH as a loading 
control. (B) We performed total lysis and left untreated (-) or treated (+) these lysates with an inhibitor of 
glycosylation, PNGaseF, revealing with anti-V5 antiboy and used GAPDH as a loading control. (Adapted from 
Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
 
Defective IFN-γ response in overexpressed IFNGR2 mutants 
We then assessed the functional consequences of c.1A>G and c.4delC mutations. We 
transiently transfected EV, WT, c.1A>G, c.4delC, and c.278delAG in IFN-γR2-deficient 
SV40-fibroblasts. We then either left the cells unstimulated (NS) or stimulated them with 
IFN-γ (105IU/ml) for 20 minutes. Nuclear proteins were extracted and GAF-DNA binding 
activity was assessed by EMSA with a GAS probe. As expected, cells transfected with the 
WT-IFNGR2 plasmid displayed high binding activity after stimulation, whereas cells 
transfected with EV or the negative control did not show any activity (Figure 10A). 
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Interestingly, cells transfected with c.1A>G or c.4delC cDNA showed impaired, but not 
abolished, responses to IFN-γ (Figure 10A). These findings correlate with the protein 
expression levels, showing that both c.1A>G and c.4delC IFNGR2 mutants encode IFN-γR2 
proteins with reduced but not abolished expression and function. In order to compare the 
observed activity with previously reported forms of partial AR deficiency, we tested the five 
corresponding hypomorphic mutations (G227R, G141R, S124F, R114C and 
c.958insT)166,189–191. After stimulation, the mean level of binding followed a gradient: WT > 
G227R > c.1A>G > G141R> c.958insT> S124F> R114C> c.4delC> c.278delAG (Figure 
10B), where overexpressed c.1A>G showed one of the strongest bindings and c.4delC 
showed the lowest binding, with G227R and c.1A>G being the least deleterious of all tested 
alleles in overexpression. We then transfected SV40-fibroblasts from P1 (cells from P3 were 
not available) with WT IFNGR2 and their response to IFN-γ was evaluated by EMSA. GAF 
binding activity was restored in the transfected cells, when compared with EV-transfected 
and un-transfected cells (Figure 10C). These results strongly suggested that the c.1A>G 
mutation of IFNGR2 is responsible for the poor response to IFN-γ observed in the 
overexpression system. Collectively, these data indicated that the patients from the two 
kindreds had a severe form of AR partial IFN-R2 deficiency. 
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Figure 10 - Impaired STAT1-DNA-binding activity in response to IFN-γ stimulation in vitro and 
complementation of the IFN-γ response with WT IFNGR2. (A) IFN-γR2-/- SV40-fibroblats were left NT or 
were transiently transfected with EV, WT, c.1A>G, c.4delC and c.278delAG IFNGR2 plasmids. (B) IFN-γR2-
/- SV40-fibroblasts (SV40F) were transiently transfected with EV, WT, c.1A>G, c.4delC, c.278delAG, G141R, 
G227R, 958insT, S124F and R114C (these last five are reported AR partial IFNGR2 mutations) IFNGR2 
plasmids. (C) SV40-fibroblasts from a healthy control and P1 were left NT or were transiently transfected with 
EV and WT IFNGR2 plasmid. (A), (B) and (C) were either left NS or stimulated with 105 IU/ml of IFN-γ (IFN-
γ). DNA-binding activity was then analyzed by EMSA with a GAS probe in LI-COR, A700. (Adapted from 
Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
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STAT1 phosphorylation upon IFN-γ stimulation in SV40 fibroblasts 
Interestingly, a mutation of the first ATG of IFNGR1 has previously been described 
in a patient with MSMD, where the first methionine is replaced by a lysine (p.M1K).192 In 
homozygous EBV-B cells for this IFNGR1 mutation, the response to IFN-γ is impaired but 
not abolished, whereas it is completely abolished in the corresponding SV40-fibroblasts. We 
set out to compare the early response to IFN-γ and IFN-α (as a control of stimulation) of 
SV40-fibroblasts from a healthy control, P1, P2 (cells from P3 being not available), a patient 
with AR complete IFN-γR2 deficiency (homozygous for the c.278delAG mutation, hereafter 
referred to as negative control), a patient with AR complete IFN-γR1 deficiency (compound 
heterozygous for the c.104_107dupTTAC and c.200+1G>A mutations), three patients with 
AR partial IFN-γR2 deficiency166,189 (corresponding to S124F, G141R and R114C), and the 
patient with AR partial IFN-γR1 deficiency due to the p.M1K mutation (hereafter referred to 
as M1K). We assessed the ability of these cells to phosphorylate tyrosine 701 of STAT1 (p-
Y701-STAT1) after IFNs stimulation by western blotting. The healthy control showed p-
STAT1 after stimulation with IFN-γ, whereas the negative control, the AR complete IFN-
γR1 deficient cells and the M1K-IFN-R1 deficient patient did not show any response (Figure 
11A). Cells from the three patients with AR partial IFN-γR2 deficiency had impaired, but 
not abolished, response to IFN-γ. Both P1 and P2 showed an equally and profoundly 
diminished response (Figure 11B), not abolished but lower than that of the three other 
patients with AR partial deficiency. The response was however detectable, unlike in cells 
from the patient mutated in the initiation codon of IFNGR1. The phosphorylation after IFN-
α was found to be comparable in all cell lines (Figure 11). The levels of GAPDH were also 
similar across cell lines, attesting that the differences of STAT1 phosphorylation were not 
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caused by differences in protein loading. The IFN-γ signaling pathway is shown to be 
impaired but not abolished in the SV40-fibroblasts of P1 and P2, unlike in the M1K-IFN-
γR1 SV40-fibroblasts, which show a complete abolition of IFN-γ signaling in terms of 
phosphorylation of STAT1. 
 
Figure 11 - Impaired phosphorylation of STAT1 in P1’s and P2’s SV40-fibroblasts after IFN-γ stimulation. 
(A) SV40-fibroblasts from a healthy control (C+), an IFN-γR2 deficient patient (IFN-γR2 -/-), an IFN-γR1 
deficient patient (IFN-γR1 -/-), P1, an IFN-γR1 patient mutated on the first methionine (IFN-γR1-M1K) and 
three recessive partial IFN-γR2 patients (S124F, G141R and R114C). (B) SV40-fibroblasts from a healthy 
control (C+), an IFN-γR2 deficient patient (IFN-γR2-/-), P1 and P2. (A) and (B) cells were left NS or were 
stimulated with 105 IU/ml of IFN-γ (IFN-γ) or IFN-α (IFN-α) for 20 minutes. Phosphorylation of STAT1 in 
Tyr-701(p-STAT1), total levels of STAT1 and levels of GAPDH (as loading control) were measured by western 
blot using specific antibodies. Upper panel: IFN-γ stimulation, lower panel: IFN-α stimulation. (Adapted from 
Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
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DNA binding and late response to IFN-γ stimulation in SV40 fibroblasts 
We next studied the ability of IFN- to stimulate the formation of GAS-binding 
nuclear complexes by EMSA. We performed the same activation as for the western blot in 
SV40-fibroblasts. The healthy control showed binding activity after stimulation with IFN-γ, 
whereas the negative control and the M1K patient did not show any binding (Figure 12A). 
Interestingly, P1 and P2 showed an equally and profoundly diminished, but detectable, 
binding activity after IFN-γ stimulation. The binding after IFN-α was found to be similar in 
all cell lines (Figure 12A), confirming the results seen by western blot. We then analyzed 
later events in the IFN-γ pathway, and measured the induction of HLA-DR after stimulation 
of two concentrations of IFN-γ stimulation (10 or 103 UI/ml) for 48 hours. The healthy 
control’s cells showed an increase of HLA-DR with the low concentration of IFN-γ, and a 
higher increase with the higher dose, whereas the negative control and M1K-IFN-γR1 cells 
showed no expression for either concentration (Figure 12B). S124F and R114C cells did not 
induce HLA-DR for both concentrations of IFN-γ (Figure 12B). In G141R cells, low 
concentrations of IFN-γ did not induce HLA-DR expression, whereas higher concentrations 
did, albeit to a lower extent than in control cells (Figure 12B). The results obtained for these 
patients with AR partial IFN-γR2 deficiency are consistent with previous reports166. P1 and 
P2 cells displayed a slight increase in HLA-DR expression in the presence of low 
concentrations of IFN-γ, higher than the other three AR partial IFN-γR2 patients tested, and 
a stronger increase in response to higher concentrations, much lower than that of the healthy 
control but similar to the G141R patient and higher than the S124F and R114C patients 
(Figure 12B). Thus, both early and late events in the IFN-γ signaling pathway are impaired 
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but not abolished in the SV40-fibroblasts of P1 and P2, unlike in the M1K-IFN-γR1 SV40-
fibroblasts, which show a complete abolition of IFN-γ signaling. 
 
Figure 12 - Impaired response of P1’s SV40-fibroblasts to IFN-γ stimulation. (A) SV40-fibroblasts from a 
healthy control (C+), an IFN-γR2 deficient patient (IFN-γR2 -/-), P1 and P2 were left NS or were stimulated 
with 105 IU/ml of IFN-γ (IFN-γ) or IFN-α (IFN-α) for 20 minutes and GAS probe-binding nuclear proteins 
were measured by fluorescent EMSA with LI-COR, A700. (B) SV40-fibroblasts from a healthy control (C+), 
an IFN-γR2 deficient patient (IFN-γR2 -/-), P1, P2 the IFN-γR1 patient mutated on the first methionine (IFN-
γR1-M1K) and three recessive partial IFN-γR2 patients (S124F, G141R and R114C) were stimulated with the 
indicated doses of IFN-γ for 48 hours. HLA-DR induction was determined by flow cytometry. Overlapping 
histograms are represented relative to mode. Gray area: no stimulation (NS), continuous black line: 10 IU/ml 
IFN-γ, discontinuous black line: 103 IU/ml IFN-γ. The results shown are representative of 3 independent 
experiments. (Adapted from Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
 
STAT1 phosphorylation upon IFN-γ stimulation in EBV-B cells 
We then characterized EBV-B cells from P1 (P2 and P3 EBV-B cells were not 
available). We analyzed the early response to IFN-γ and IFN-α of a healthy control, P1, the 
AR complete IFN-γR2 deficient patient (homozygous for c.278delAG), an AR complete 
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IFN-γR1 deficient patient (homozygous for the c.202-1G>T mutation), S124F, G141R, 
R114C, cells from a patient with AD partial IFN-γR2 deficiency167 (heterozygous for the 
c.186delC mutation), and M1K-IFN-γR1 deficiency. We first assessed the ability of these 
cells to phosphorylate STAT1 after IFNs stimulation, as measured by western blotting. The 
healthy control showed p-STAT1 after stimulation with IFN-γ, whereas the negative control, 
the AR complete IFN-γR1 and the M1K patient did not show any response (Figure 13). P1 
showed a severely impaired, but not abolished, response to IFN-γ (Figure 13). The three 
patients with IFN-γR2 partial deficiency previously reported, and the AD c.186delC patient, 
had an impaired, but not abolished, response to IFN-γ (Figure 13). The phosphorylation of 
STAT1 in response to IFN-α was found to be comparable in all cell lines (Figure 13). The 
levels of GAPDH were also similar across cell lines, attesting that the differences of STAT1 
phosphorylation were not caused by differences in protein loading. The IFN-γ signaling 
pathway is severely impaired in terms of phosphorylation of STAT1 by western blot in the 
EBV-B cells of P1. 
 
Figure 13 – Impaired phosphorylation of STAT1 in P1’s EBV-B cells after IFN-γ stimulation. EBV-B cells 
from a healthy control (C+), an IFN-γR2 deficient patient (IFN-γR2 -/-), an IFN-γR1 deficient patient (IFN-γR1 
-/-), P1, an IFN-γR1 patient mutated on the first methionine (IFN-γR1-M1K), three recessive partial IFN-γR2 
RESULTS- Chapter I – IFN-γR2 deficiency 
 Page 81 
     
patients (S124F, G141R and R114C) and a dominant partial IFN-γR2 patient (c.186delC) were left NS or were 
stimulated with 105 IU/ml of IFN-γ (IFN-γ) or IFN-α (IFN-α) for 20 minutes. Phosphorylation of STAT1 in 
Tyr-701 (p-STAT1), total levels of STAT1 and levels of GAPDH (as loading control) were measured by 
western blot using specific antibodies. Upper panel: IFN-γ stimulation, lower panel: IFN-α stimulation. 
(Adapted from Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
Abolished DNA-binding activity upon IFN-γ stimulation in P1’s EBV-Bs 
We investigated the ability of STAT1 homodimers to bind to the GAS probe by 
EMSA in EBV-B cells. We performed the same activation as for the western blot in cells 
from a healthy control, the negative control, the AR complete IFN-γR1 patient, P1, IFN-γR2 
(S124F, G141R, R114C, c.186delC), and IFN-γR1 (M1K) deficient cells. As expected, the 
healthy control showed binding activity after stimulation with IFN-γ, unlike the negative 
control and the AR complete IFN-γR1 patient (Figure 14A). Consistent with what has been 
published, G141R, S124F, R114C, and c.186delC showed impaired but not abolished 
binding to GAS after IFN-γ stimulation (Figure 14A). As for P1 and the M1K IFN-
γR1patient, no GAS binding was detected (Figure 14B). The binding after IFN-α was found 
to be more or less similar in all cell lines (Figure 14). This result supports the hypothesis that 
IFNGR2 c.1A>G mimics IFNGR1 M1K in EBV-B cells. However, the defect in P1’s EBV-
B cells is more pronounced than that in P1’s SV40-fibroblasts, whereas it is the opposite for 
the M1K IFN-γR1 patient. The impact of the mutations of the first methionine of the two 
chains of the IFN-γ receptor seems to depend on the mutated chain and the cell type tested. 
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Figure 14 - Impaired GAS binding of P1’s EBV-B cells after IFN-γ stimulation (A) EBV-B cells from a healthy 
control, a negative control, P1, three recessive partial patients and an autosomal dominant patient. (B) EBV-B 
cells from a healthy control, P1, the IFN-γR1 M1K patient, a negative control for IFN-γR2 (IFN-γR2 -/-) and a 
negative control for IFN-γR1 (IFN-γR1 -/-). (A) and (B) cells were left non stimulated (NS) or were stimulated 
with 105 IU/ml of IFN-γ (IFN-γ) or IFN-α (IFN-α) for 20 minutes and GAS probe-binding nuclear proteins 
were measured by radioactive EMSA, p32 dATP. Upper panel: IFN-γ stimulation, lower panel: IFN-α 
stimulation. (Adapted from Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185  
 
Impairment of IFN-γ signaling in fresh leukocyte subset 
 IFN-γR2-deficient patients show high levels of IFN-γ in their plasma and low or 
abolished production of IL-12p40 and IL-12p70 in their whole blood after BCG and IFN-γ 
stimulation.35 We measured IFN-γ levels in the plasma of P1, P2, and P3 by ELISA, and 
compared them with healthy controls and patients with complete or partial IFN-γR2 
deficiency. The healthy controls and the patient with AD partial IFN-γR2 deficiency showed 
no detectable IFN-γ in their plasma, whereas P1, P2, and P3 showed high IFN-γ levels in 
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their plasma, which were similar to the levels observed in patients with AR partial IFN-γR2 
deficiency, whether complete or partial (Figure 15).  
 
Figure 15 - IFN-γ levels in plasma from P1, P2, P3, AR complete IFN-γR2 deficient patients (n=16), AR partial 
IFN-γR2 deficient patients (n=5), AD partial patient (n=2) and healthy controls (n=22). (Adapted from Oleaga-
Quintas et al. Human Molecular Genetics; 2018; in press)185 
 
We also assessed the IFN-γ, IL-12p40 and IL-12p70 production of whole blood from 
healthy controls, P1, and P2 (P3 was not available) after 48 hours stimulation with live BCG, 
with or without IFN-γ or IL-12, as previously described,169 as compared with patients with 
complete or partial IFN-γR2 deficiency. Healthy controls, IFN-γR2-deficient patients, P1, 
and P2 showed similar secretion of IFN-γ after BCG stimulation and a higher production 
after BCG and IL-12 (data not shown). All individuals tested showed production of IL-12p40 
after BCG stimulation, but no IL-12p70 production (Figure 16B). When stimulating with 
both BCG and IFN-γ, the healthy controls showed a higher increase in IL-12p40 production 
compared with BCG alone (Figure 16A), as well as an induction of IL-12p70 production 
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(Figure 16B). In contrast, patients with AR complete IFN-γR2 deficiency did not show any 
response, in terms of the production of IL-12p40 in response to BCG plus IFN-γ, compared 
with BCG alone, and that of IL-12p70 in response to either stimulation (Figure 16). Patients 
with AR partial IFN-γR2 deficiency showed an increase in IL-12p40 levels, upon stimulation 
with BCG plus IFN-γ, yet lower than controls (Figure 16A). Patients with an AR partial 
defect showed no IL-12p70 production, whereas those with an AD partial defect showed a 
normal production of IL-12p70 (Figure 16B). P1 and P2 also showed an increase of IL-12p40 
in response to BCG plus IFN-γ, and no IL-12p70 production, like known patients with an 
AR partial IFN-γR2 deficiency (Figure 16). These results showed that the IFN-γR2 
deficiency in P1 and P2 is more severe than that in previously reported patients with AR IFN-
γR2 partial deficiency but less so than in patients with AR complete IFN-γR2 deficiency. 
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Figure 16 - Impaired response to IFN-γ in terms of the production of IL-12 in the whole- blood supernatant 
from the patients. (A) Production of  IL-12p40 and (B) IL-12p70 in whole blood cells from local controls, travel 
controls, AR complete IFN-γR2 deficient patients, AR partial IFN-γR2 deficient patients, AD partial patient, 
P1 and P2 either NS or stimulated for 48 hours with live BCG alone or live BCG plus IFN-γ, as assessed by 
ELISA. Each symbol represents a value from an independent test and horizontal bars represent means. (Adapted 
from Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
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 Study of individual leukocyte subsets 
We then investigated the consequences of the c.1A>G mutation in fresh leukocyte 
subsets from two healthy controls, P1, P2, and an AR complete IFN-γR2 deficient patient 
(c.278delAG mutation). It has been previously reported that p-STAT1 levels in AD partial 
IFN-γR2 patient’s naive CD4+ T cells and memory interleukin (IL)-4 producing T cells 
responded poorly to IFN-γ, whereas MDMs did not.167 We tested naïve CD4+ T cells and 
MDMs generated by stimulation of monocytes in vitro with M-CSF plus IL-4 (monocytes 
from the AR complete IFN-γR2-deficient patient were not available). The different cell 
subsets were stimulated with IFN-γ and IFN-α, as previously done. In naïve CD4+ T cells a 
slight phosphorylation of STAT1 was observed in P1 and P2 after IFN-γ stimulation, whereas 
in the healthy controls the levels of p-STAT1 were high and in the IFN-γR2-deficient patient 
phosphorylation was not detected (Figure 17A). MDMs from P1 and P2 showed a slight 
phosphorylation after IFN-γ stimulation, much lower than the healthy controls but not 
abolished (Figure 17B). The levels of p-STAT1 after IFN-α stimulation were comparable 
between all cell types (T lymphocytes and MDMs) of the patients and the controls (Figure 
17). Total STAT1 levels were similar among all points and GAPDH was used as a loading 
control (Figure 17). These results correlate with published data167, and the c.1A>G mutation 
seems to affect more strongly the cell types that normally express low levels of IFN-γR2 at 
their surface. They also support the hypothesis that the c.1A>G mutation confers partial 
activity of IFN-γR2, lower than that of the known hypomorphic mutations underlying AR 
partial IFN-γR2 deficiency. 
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Figure 17 - Functional study of T cells and MDMs. (A) CD4+ naïve T cells from two healthy controls (C1 and 
C2), an IFN-γR2 deficient patient (IFN-γR2-/-), P1 and P2. (B) CD14+ cells from a healthy control (C1), P1 and 
P2 were isolated and differentiated to MDMs. (A) and (B) cells were isolated and left NS or were stimulated 
with 105 IU/ml of IFN-γ (IFN-γ) or IFN-α (IFN-α) for 20 minutes. Phosphorylation of STAT1 in Tyr-701(p-
STAT1), total levels of STAT1 and levels of GAPDH or tubulin (as loading control) were measured by western 
blot using specific antibodies. Upper panel: IFN-γ stimulation, lower panel: IFN-α stimulation. (Adapted from 
Oleaga-Quintas et al. Human Molecular Genetics; 2018; in press)185 
 
Lack of re-initiation of translation at distal AUG 
 Several studies have shown that the most common start of translation in mammalian 
mRNA is at an AUG codon in a favorable context for translation initiation, which is -3 A or 
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G and + 4 G, collectively defining a Kozak consensus sequence.193–195 These two mutations, 
c.1A>G and c.4delC, underlie a novel form of AR partial IFN-γR2 deficiency, where the 
expressed receptor is poorly abundant but normal. It is a quantitative, as opposed to the 
qualitative defect previously reported for mutations p.G227R, p.G141R, p.R114C, p.S124F 
and c.958insT. We thus attempted to identify the amino-acid responsible for the initiation of 
the residual IFN-γR2 expression. We searched in the IFNGR2 sequence an AUG codon 
downstream of c.1ATG that could match these characteristics through the Prediction of 
Translation Initiation ATG Web site (http://atgpr.dbcls.jp).196 The next AUG predicted to re-
initiate translation (and the next AUG in the sequence) is located in position c.238, aminoacid 
position 80. Usage of this initiation codon would lose the leader sequence and part of the 
extracellular domain. We, nevertheless, constructed several plasmids designed as “Start” 
[c.1delATG (Start2), c.1delATGC (Start2 + c.4delC), c.238AT>GC (M80A), c.1_237del 
(Start80) and Start2 + M80A] to define the start of translation after position c.4, and test if 
there would be IFN-γR2 protein expression by deleting the first 237 base pairs (first 79 
aminoacids) or changing the methionine in this position by an alanine (Figure 18A). All the 
mutants except Start80 resulted in a product of normal MW but weaker intensity than WT 
IFNGR2, although it was stronger than that of c.1A>G (Figure 18B). In the case of Start80, 
no product was detected, similar to what is observed with c.278delAG point serving as a 
negative control (Figure 18B). As expected, these data ruled out a re-initiation of translation 
by the Kozak codon c.238. 
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Figure 18 - Study of potential initiation codons. (A) Schematic representation of the IFNGR2 gene cloned in a 
pcDNA3.1-V5 plasmid. The positions of various translation start codon candidates in the signal peptide and 
mutations are indicated. (B) HEK 293-T cells were either left NT or were transiently transfected with EV, WT 
IFNGR2, c.1A>G, c.4delC, c.278delAG, Start80, Start2, M80A, Start2 combined with M80A or Start2 
combined with c.4delC. After 48 hours we performed total lysis and revealed by western blot with anti-V5 
antibody and used GAPDH as a loading control. (Adapted from Oleaga-Quintas et al. Human Molecular 
Genetics; 2018; in press)185 
 
 Re-initiation of translation at a proximal non-canonical codon 
Instead, these data suggested that the two mutants c.1A>G and c.4delC were 
hypomorphic due to initiation of translation at a non-AUG codon, most likely within the 
leader sequence (signal peptide) of IFN-γR2, and even possibly, in the case of c.1A>G, by 
the first codon itself (GUG).197 Indeed, translation can be carried out through non-AUG 
codons such as CUG, GUG and ACG.198–200Analyzing the IFNGR2 sequence, we found that 
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there was one ACG codon at position c.10, two consecutive CTG codons starting at positions 
c.13 and five consecutive CTG codons starting at position c.25. Using a signal peptide 
predictor (http://www.predisi.de), PrediSi201, we deleted in silico aminoacids of IFN-γR2 
from M1 until no signal peptide was predicted, which happened at L10 (c.28CTG). We then 
created plasmids starting at different non-AUG codons until the predicted loss of the signal 
peptide (Start 2, 4, 6, 8, 10 and 14) (Figure 18A). IFN-γR2 was expressed at the expected 
MW (70 kDa) for the mutations encompassing the start at aminoacids 2, 4, 6 and 8 at lower 
levels than the WT (Figure 19). The Start2 mutation produced similar proteins levels to the 
c.4delC mutation, whereas Start4 and Start6 produced similar protein levels to the c.1A>G 
mutation, with Start8 being lower than both of the mutations reported in this study (Figure 
19). Both Start10 and Start14 did not show any detectable protein expression, correlating 
with the predictions made in silico (Figure 19). This result suggested that there are several 
codons involved in the translation of IFNGR2, all within the signal sequence, and that 
c.1ATG codon is the strongest site for the start of translation. This hypothesis was confirmed 
by immunoprecipitation and protein sequencing of the overexpressed IFN-γR2 WT, c.1A>G 
and c.4delC. A full-length protein from position 22 (position after the leader sequence is cut) 
to 337 (last aminoacid of IFN-γR2) was detected for the three lysates tested. Altogether, these 
results show that the two novel mutations herein described encode, at lower levels than the 
WT, a full-length mature IFN-γR2 due to initiation of translation by non-AUG codons 
located between codons two and nine within the 21-long signal peptide. 
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Figure 19 – Identification of reinitiation of translation points. HEK 293-T cells were either left NT or were 
transiently transfected with EV, WT, c.1A>G, c.4delC, c.278delAG, Start2, Start4, Start6, Start8, Start10 and 
Start14 IFNGR2 plasmids. After 48 hours total lysis was performed and revealed by western blot with anti-V5 
antibody and used GAPDH as a loading control. (Adapted from Oleaga-Quintas et al. Human Molecular 
Genetics; 2018; in press)185
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Chapter II – GATA2 deficiency 
Demographics and diagnosis of GATA2 deficiency in 14 unrelated kindreds 
We studied 14 index cases and three symptomatic relatives from 13 non-
consanguineous families and one consanguineous family with mycobacterial diseases and 
hematological anomalies, adding up to a total of 17 patients (Figure 20) who were referred 
to the laboratory of Human Genetics of Infectious Diseases between 2011 and 2018. Patients 
are from Brazil (kindred A and B), Colombia (C), France (D and E), Germany (F), Mexico 
(G), Portugal (H), Spain (I, J and K), Tunisia (L), Turkey (M), and USA (N). Kindred D and 
E were reported in a previous study.126 Using Sanger sequencing, we determined the 
sequences of seven coding exons and flanking intronic regions of GATA2 in 10 of the 14 
patients (P2-P5, P9, P11-P13, P15 and P17). WES was performed in 4 of the 14 patients (P1, 
P7 P8 and P16). We identified five missense mutations [c.1163T>C (p.M388T) in kindred A 
and J, c.1193G>A (p.R398Q) in kindred D, c. 1192C>T (p.R398W) in kindred B and F, 
c.1187G>A (p.R396Q) in kindred G and c.1186C>T (p.R396W) in kindred M], one nonsense 
mutation [c.988C>T (p.R330*) in kindred I], one insertion [c.1035_1036insTCTGGCC 
(predicted p.G346Sfs*40) in kindred K], two duplications [c.599dup (predicted p.S201*) in 
kindreds H and L and c.1099dup (predicted p.D367Gfs*17) in kindred N] and two deletions 
[c.915_916del (predicted p.W306Afs*77) in kindred C and c.1023del (predicted 
p.A342Pfs*45) in kindred E], all in heterozygosity (Figure 20). Ten mutations have 
previously been reported in other patients,119,121,123,126,127,202–204 whereas one is novel 
(c.1035_1036insTCTGGCC). This novel variant was not found in public databases (ExAC, 
GnomAD and BRAVO database) or in our own WES database of around 4,500 exomes of 
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patients with a variety of infectious diseases. We analyzed the familial segregation of the 
mutant alleles in the 14 kindreds. Three family members with clinical features suggestive of 
GATA2 deficiency (Mycobacterial disease and cutaneous warts for P6; pulmonary 
tuberculosis for P14; mycobacterial disease and MDS for P10) were found to be heterozygous 
for GATA2 mutations. Seventeen individuals were WT. Surprisingly, 16 individuals were 
carriers of a GATA2 mutation, but not clinically affected (Kindreds A, B, D, J, L, M and N; 
Figure 20). Biological material was not available for other 18 individuals (Figure 20). 
Collectively, these data suggested that 33 individuals (17 patients and 16 carriers) had AD 
GATA2 deficiency 
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Figure 20 - Schematic representation of the 14 kindreds with germline GATA2 mutations. Each kindred is 
designated by a capital letter (A-N), each generation by a roman numeral (I-II), and each individual by an Arabic 
number. The proband is indicated by arrows. Solid black shapes indicate GATA2 deficient patients and clinical 
disease. Solid grey shapes indicate individuals with GATA2-related clinical features (lymphedema or AML) 
but not genotyped. Individuals crossed with a black vertical line represent asymptomatic GATA2 deficiency. 
Individuals crossed with a diagonal black line represent deceased members. Healthy individuals are shown in 
white. 
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Expression of the mutant GATA2 alleles in HEK293-T cells 
Human GATA2 encodes two isoforms: Isoform 1 with 480 aminoacids (aa, 50.5 kDa) 
and isoform 2 with 466 aa (49.1 kDa).113 We evaluated the expression of the GATA2 protein 
by transiently transfecting HEK293-T cells with constructs encoding C-terminally DDK-
tagged WT or mutant GATA2 cDNAs. Similar levels of GATA2 mRNA were detected in 
HEK293-T cells with WT or mutant alleles (data not shown). The WT GATA2 protein was 
detected by western blot at the expected MW (50 kDa). The missense mutants (p.M388T, 
p.R396Q, p.R396W, p.R398Q and p.R398W) were expressed at the expected MW (50 kDa), 
like the WT. The protein expression levels for all missense mutations were normal for both 
isoforms, as detected with both GATA2- and DDK-specific antibodies (Figure 21). The c. 
1099dup, c.599dup, c.1035_1036insTCTGGCC, c.915_916del, c.1023del and p.R330* 
mutants produced a truncated protein for isoform 1, as detected with an antibody against 
GATA2 (Figure 21). Protein levels were lower than the WT for the c.599dup, 
c.1035_1036insTCTGGCC and c.915_916del for isoform 1, whereas c.1099dup, p.R330* 
and c.1023del produced protein levels similar to the WT. c.1035_1036insTCTGGCC and 
c.1023del are part of the intron for isoform 2, therefore not being present in the isoform 2 
constructs. The c. 1099dup, c.915_916del and p.R330* produced a truncated protein for 
isoform 2, as detected with the antibody against GATA2, while the mutant c.599dup did not 
show detectable protein expression for this isoform (Figure 21).  
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Figure 21 - Protein expression of GATA2 alleles in overexpression system. HEK293-T cells either left NT or 
were transfected with an EV, a construct encoding GATA2 WT-DDK-tagged or mutated alleles corresponding 
to isoform 1 (A) or isoform 2 (B) of GATA2 (p.R330*, c.1099dup, c.599dup, p.R398Q, p.M388T, 
c.1035_1036insTCTGGCC, p.R398W, p.R396Q, p.R396W, c.915_916del and c.1023del) for 48 hours. 
GATA2 protein expression was evaluated by western blotting with an anti-GATA2 antibody and an anti-DDK 
tag. GAPDH was included as loading control.  
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Functional activity of the mutant GATA2 alleles in HEK293-T cells  
We then assessed the functional activity of the GATA2 mutants by luciferase assay 
in HEK293-T cells transfected with the different cDNAs. Only isoform 1 of GATA2 has 
transcriptional activity. The promyelocytic leukemia protein (PML) gene is a member of the 
tripartite motif (TRIM) family that has been reported to potentiate the transactivational 
activity of GATA2.205 Thus, we evaluated the impact of the different mutant alleles in 
comparison with GATA2-WT, with or without PML. HEK293-T cells transfected with 
GATA2-WT showed a functional activity that was enhanced when the cells were co-
transfected with PML (Figure 22). However, the function of the different GATA2 alleles was 
severely impaired or abolished in both conditions depending on the allele tested, being 
statistically significantly different from the WT (Figure 22). The missense alleles (p.M388T, 
p.R396Q, p.R396W, and p.R398Q) showed an impaired but not completely abolished 
luciferase activity compared to the WT, suggesting that these alleles are functionally 
hypomorphic, whereas one missense (p.R398W), the nonsense (p.R330*) and frameshift 
alleles (c.599dup, c.915_916del, c.1023del, c.1035_1036insTCTGGCC and c.1099dup) are 
complete LOF, at least in these conditions of over-expression (Figure 22).  
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Figure 22 - Functional characterization of GATA2 alleles. Luciferase activity of GATA2 measured in HEK293-
T cells. GATA2-dependent transactivation potential was evaluated with GATA2 luciferase reporter plasmid. 
Cells were transiently transfected with (+) or without (-) PML, EV and different GATA2-plasmids (WT, 
p.R330X, p.M388T, p.R396W, p.R396Q, p.R398Q, p.R398W, c.599dup, c.915_916del, c.1023del, 
c.1035_1036insTCTGGCC and c.1099dup). 
 
Study of the mechanism of dominance in HEK293T cells 
Afterwards, we studied the mechanism underlying dominance (haploinsufficiency or 
dominance negative) in heterozygous cells. We performed luciferase assays in transient co-
transfections with PML and constant levels of WT, changing the amount of mutant plasmid 
and compensating with EV to reach the same final concentration (Figure 23). The luciferase 
activity for the different amounts of mutant plasmid was constant and increased compared to 
the EV, being not statistically significant when compared to the corresponding WT with EV 
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point (Figure 23). This result strengthens the hypothesis that GATA2 deficiency is caused by 
haploinsufficiency, since the luciferase activity is predicted to decrease in the presence of 
higher amounts of mutant plasmid in a dominance negative model.  
 
Figure 23 – Dominance test for GATA2 mutant alleles. Transient co-transfection of cells with PML and constant 
amount GATA2-WT plasmid (25 ng) with decreasing amounts of mutant plasmids (p.R330X, p.M388T, 
p.R396W, p.R396Q, p.R398Q, p.R398W, c.599dup, c.915_916del, c.1023del, c.1035_1036insTCTGGCC and 
c.1099dup), different amounts of EV were used to keep the final plasmid concentration constant. Error bars 
indicate standard error of the mean. NS stands for not significant in the statistical analysis. 
 
In addition, we analyzed several selection parameters, to estimate the evolutionary 
pressure on the GATA2 locus (see methods). GATA2 has a pLI score of 0.97 (Figure 24A) 
(being 0.9 the threshold where genes are said to be extremely intolerant to LOF variants). 
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Moreover, GATA2 was found to be under negative selection when considering the f parameter 
from SnIPRE, which is 0.388 (Figure 24B) (95% confidence interval: 0.223 - 0.675), placing 
GATA2 in the 26.4% of the genes under the strongest evolutionary pressure. The RVIS score, 
with a value of 11.839 (Figure 24C), places GATA2 in the 11.8% of genes under the strongest 
negative pressure. These results highly suggest that GATA2 has evolved under purifying 
selection, strengthening the hypothesis that GATA2 deficiency results from haplo-
insufficiency.123,206–208 
 
Figure 24 - List of variants and strength of purifying selection on GATA2. Genome-wide distribution of the 
strength of purifying selection, estimated by the (A) pLI score, (B) f Parameter, and (C) RVIS score in bar plots, 
as described in the methods. The position of GATA2 is indicated by a black arrow and a red vertical bar. 
 
 
RESULTS - Chapter II – GATA2 deficiency 
 Page 102 
    
Environmental mycobacterial diseases in GATA2 deficient patients 
The mycobacterial diseases in the patients were caused by EM (n=9), M. tuberculosis 
(n=4), EM and M. tuberculosis (n=1) and undefined Mycobacterium species (n=3) (Figure 
25A). Ten patients developed EM disease due to M. avium (n=4) and/or M. kansasii (n=7). 
One of these patients (P5) had two different EM infectious diseases caused by M. avium and 
M. kansasii and P1 displayed combination of EM disease and tuberculosis. Recurrence of 
EM disease was observed in P15 who developed an infection by M. kansasii affecting lymph 
nodes at 24 years, and three years later, the patient suffered from a disseminated infection. 
No other EM was identified in this cohort. Mean age at EM diagnosis was 21 years (range 
12 years to 29 years). The diagnosis of EM was made by positive culture (n=9), PCR (n=4), 
direct detection of acid-fast bacilli (n=2), or clinical suspicion (n=2). Positive culture was 
documented in two sites (n=4), lung and blood (n=3), or liver and blood (n=1). The sites for 
EM disease were the lungs (n=7), lymph nodes (n=5), liver (n=3), spleen (n=2), and bone 
marrow (n=3) (Figure 25B). Up to four organs were affected in infections with EM. In this 
cohort, EM disease has been not reported to affect soft tissues or the skin. Most episodes 
involved simultaneous infection of the lung and lymph nodes. Disseminated EM disease was 
documented in seven patients (P5, P6, P7, P8, P9, P13 and P17). Three patients with 
pulmonary EM disease had fever and coughing (P2, P6 and P17) and three patients had chest 
pain, fever and coughing (P5, P7 and P12).  
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Figure 25 - Mycobacterial infections and distribution in GATA2 deficient patients. (A) Spectrum of 
mycobacterial species infecting GATA2 deficient patients. Patients affected by a type of mycobacterial species 
are represented by percentages, considering infections by two different species as a type of infection. 
Asymptomatic carriers represent those individuals carrying the mutation with no clinical phenotype. (B) 
Mycobacterial infection sites in patients with EM infection. Sites of infection are represented by percentages. 
 
Tuberculosis in GATA2-deficient patients 
Twelve of the 17 patients studied here received BCG vaccination at birth. However, 
complications caused by this vaccine were not reported in this cohort. TB has been diagnosed 
in five patients (P1, P3, P14, P15 and P16). All patients with tuberculosis had been vaccinated 
with BCG. Mean age at tuberculosis diagnosis was 29 years (range 17 years to 42 years). 
Tuberculosis was thoracic in four patients (P1, P3, P14 and P15) and disseminated in one 
patient (P16). The diagnosis of tuberculosis was confirmed in two patients (P1 and P16) by 
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positive culture of M. tuberculosis, whereas probable tuberculosis was diagnosed otherwise 
in three other patients (P3, P14 and P15). In this cohort, tuberculosis was mostly found in the 
lungs (n=4) (Figure 26). Recurrence of tuberculosis has been documented in P3 who had two 
pulmonary episodes (28 years and 32 years) and P16 (29 years and 31 years) who developed 
two episodes of disseminated tuberculosis affecting the lungs, lymph nodes, spleen and bone 
marrow. Patients with infections caused by undefined Mycobacterium spp. displayed 
disseminated (P4) or localized (P10 and P11) forms of infectious disease. 
 
Figure 26 – Distribution of tuberculosis infection. Mycobacterial infection sites in patients with M. tuberculosis 
infection. Sites of infection are represented by percentages. 
 
Other clinical manifestations in GATA2 deficient patients 
All patients suffered from non-mycobacterial infections, caused by viruses, bacteria, or fungi. 
The microorganisms most frequently isolated were: Streptococcus pneumoniae (n=2), 
Klebsiella pneumoniae (n=1), Citrobacter freundii (n=1), Clostridium difficile (n=2), 
Haemophilus influenzae (n=1), Pseudomona aeruginosa (n=1), Streptococcus salivarius 
(n=1). Eight patients suffered from bacterial infections other than mycobacterial infections. 
In addition, five patients displayed mucocutaneous fungal infections caused by Candida spp., 
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three of them oral infections (P3, P9 and P11), one of them cutaneous infection (P5) and 
another esophageal infection (P13). Candida infections may have been favored by certain 
cytopenia (neutropenia in particular, documented in P3 and P13) and medications (such as 
long antibiotic therapy combined or not with immunosuppressors, P13). One patient had 
disseminated histoplasmosis at the age of 23 years (P17). P5 and P12 suffered from 
disseminated aspergillosis, causing the death of P5. One patient suffered from EBV infection 
(P9). One patient suffered a fulminant hepatitis caused by HSV-2 (P10). Eight patients had 
recurrent warts caused by human papillomavirus (P1, P2, P3, P5, P6, P10, P14 and P15). P1 
required 10 days of hospitalization referred as caused by adverse reactions the yellow fever 
vaccine. In addition to infectious diseases, some patients had lymphedema (P1, P2, P5, P6, 
P14 and P115), sarcoidosis (P11 and P16), psoriasis (P5 and P16), monoclonal gammapathy 
(P11), obesity (P8), thrombosis (P8, P13 and P14), and non-infectious oral ulcers (P4 and 
P17). 
Hematological and immunological anomalies of GATA2-mutated patients 
GATA2 mRNA is expressed in total PBMCs and in different subsets of lymphoid (T cells, B 
cells, NK cells) and myeloid cells (monocytes, total dendritic cells, myeloid dendritic cells, 
plasmacytoid dendritic cells) and CD34+ cells.113,209,210 When total PBMCs were analyzed, 
GATA2 mRNA was detected in healthy controls (Figure 27). However, when we measured 
the GATA2 mRNA levels in different blood cell subsets, we observed that only CD34+ cells 
expressed detectable GATA2 mRNA (Figure 27). We then compared the healthy controls to 
the patients’ total PBMCs GATA2 mRNA levels. We observed that GATA2 mRNA levels 
were reduced in the available patients’ PBMCs (P4, P11, P13, P16 and P17), when compared 
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with controls (Figure 27D). These data are consistent with those previously reported in the 
literature, where GATA2 mRNA levels were reduced in the PBMCs of a GATA2 deficient 
patient.202 In GATA2 -/+ mice, reduced numbers of HSCs have been observed,202,211 and 
probably the same situation can occur in GATA2-deficient patients.  
 
Figure 27 - GATA2 mRNA levels in peripheral blood subsets. (A) GATA2 qPCR on lymphoid cells (NK, T and 
B cells) and total peripheral blood mononuclear cells (total PBMCs) from healthy donors (n=6). (B) GATA2 
qPCR on myeloid cells (monocytes, dendritic cells [DC], myeloid dendritic cells [mDCs] and plasmacytoid 
dendritic cells [pDCs]) and on total PMBCs from healthy donors (n=6). (C) GATA2 qPCR on hematopoietic 
stem cells (CD34+) and total PBMCs from healthy donors (n=6). (D) GATA2 qPCR on total PBMCs from P13, 
P11, P17, P4 and P16, and total PBMCs from healthy donors (n=6). Error bars indicate the standard error of the 
mean. 
Then, we evaluated the circulating blood counts and we found (when the information 
was available) that some of the patients presented low neutrophils counts (n=7), low or absent 
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B cell counts (n=15), low T cell counts (n=11), low or absent NK cells (n=14), and low 
dendritic cells (n=6). Monocytopenia was the most common feature between the patients, 
found in 16 out of 17. Bone marrow analysis was performed in twelve patients. Hypoplasia 
was observed in eight patients (P3, P5, P9, P10, P11, P13, P15 and P17), myelodysplastic 
syndrome was also observed in seven patients (P4, P5, P9, P10, P11, P13 and P15), acute 
myeloid leukemia (AML) was observed in P7, and hemophagocytic syndrome secondary to 
disseminated mycobacterial infection was observed in P13. Cytogenetic analysis was studied 
in eight patients where six patients have been referred as normal. However, two patients had 
an aberrant cytogenetic analysis resulting in deletions and aneuploidy in P10; and duplication 
(15; 1qter->1q12:15p11->15qter) in P11. FLT3L levels on plasma were increased in all the 
patients tested (n=8) and one carrier, whereas it was undetectable in four carriers (Figure 
28A); the plasma was not available for the other patients. Only two patients showed high 
levels of M-CSF in the plasma; in the others patients (n=7) (Figure 28B), the levels remained 
low.  
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Figure 28 - FLT3L and M-CSF levels in plasma of GATA2-deficient patients. (A) FLT3L and (B) M-CSF 
levels in plasma from healthy controls (n=17 and n=5 respectively, black circles), GATA2-deficient patients 
(n=8 and n=5 respectively, red triangles) and asymptomatic individuals with GATA2 mutations (n=4 and n=3 
respectively, blue squares). 
 
Penetrance calculation for GATA2 deficiency 
Next, we estimated clinical penetrance as a function of age at the first GATA2 
deficiency-related symptom in a total of 18 family members of the index cases who were 
confirmed to carry a GATA2 mutation (P14 was not considered due to lack of age 
information). Of these 18 individuals, only two presented GATA2 deficiency-related 
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symptoms (P6, at 17 years of age suffered from M. kansasii infection; and P10, at 12 years 
of age suffered from MDS). The other 16 individuals remained healthy at the last follow-up 
(follow-up range, 6 to 78 years; mean 39.33 years). The estimated clinical penetrance on 
these 18 individuals reached a plateau of 14% at 20 years (95% confidence interval [CI], 
0.02-0.36) (Figure 29A). However, only alive relatives of the index case and one dead 
relative (P10) were genetically tested for GATA2 deficiency, which can lead to ascertainment 
bias and underestimation of the penetrance. Thus, we performed a second calculation 
including four non-genotyped family members who died from diseases very likely to be 
related to GATA2 deficiency, i.e. AML or lymphedema (Kindred B, II.1 and II.3, who both 
died from AML at age 36 and 33 years respectively; kindred F, II.3 who died from AML at 
age 26 years; and kindred L, II.4 who died by lymphedema at birth, considered age 0). Using 
those 22 individuals, the penetrance was estimated at 15.5% by the age of 25 years (95% CI, 
0.034-0.35) and increased to 32.9% by the age of 40 years (95% CI, 0.12-0.55) (Figure 29A). 
This result suggests that penetrance for GATA2 deficiency increases with age, remaining 
nonetheless incomplete at the age of 40 years. As mycobacterial infections were the main 
clinical manifestation in the 14 index cases, we analyzed the penetrance of mycobacterial 
disease in comparison with the other clinical phenotypes associated with GATA2 deficiency 
(AML, viral infections or lymphedema) on the 22 individuals afore mentioned. The 
penetrance for mycobacterial disease was estimated at 10% by the age of 20 years (95% CI, 
0.017-0.3) and increased to 22.6% by the age of 40 years (95% CI, 0.06-0.44) (Figure 29B) 
whereas the penetrance for other clinical phenotypes was estimated at 10% at the age of 20 
years (95% CI, 0.15-0.28) and increased to 28% by the age of 40 years (95% CI, 0.095-0.5) 
(Figure 29B). Overall, we observed no significant differences between the penetrance for 
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mycobacterial disease or other clinical phenotypes, probably due to the low number of 
individuals available for this calculation. While the estimation of the clinical penetrance may 
be biased due to incomplete information regarding family members of the index case, (as 
illustrated by the difference observed between the two analysis strategy), observing four 
GATA2-mutation carriers who have remained physically healthy at more than 60 years of age 
(Kindred A, I.2, 78 years; Kindred B, I.2, 63 years; Kindred J, I.1, 68 years; and Kindred M, 
I.1, 66 years), confirms incomplete penetrance. These results suggest that there might be 
other elements, such as genetic modifiers or pathogen exposure that play a role in the 
development of GATA2 deficiency-related disease.212,213 
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Figure 29 - Penetrance of clinical diseases in GATA2 deficiency. (A) Kaplan-Meier curves showing penetrance 
of GATA2 confirmed carriers (GATA2 confirmed, continuous line) and family members with suspected GATA2 
deficiency (GATA2 suspected, discontinuous line) with clinical manifestations at 20 and 40 years. (B) 
Penetrance of mycobacterial infection (Mycobacterial disease, continuous line) and other clinical 
manifestations of GATA2 deficiency (Other disease, discontinuous line). 
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Clinical outcome 
We focused on the onset of mycobacterial infection and survival of the 17 patients. 
The age at onset of infection was available for 15 of these patients, being typically in early 
adulthood. The mean age at onset of the first mycobacterial infection was 23.25 years (range, 
12 to 42 years) (Figure 30). Of these onsets, eight were caused by EM (mean age 21 years-
range 12 years to 29 years) (Figure 30), four were caused by TB (mean age 29 years-range 
17 years to 42 years) (Figure 30) and three were caused by unidentified mycobacteria (mean 
age 22.6 years-range 12 to 38 years) (Figure 30). Nine of the 17 patients and all asymptomatic 
individuals are still alive (Figure 20). Their most recent follow-up visit was at a mean age of 
35 years (range 25 to 51 years) for the patients and at a mean age of 41.18 years (range 11 to 
78 years) for the asymptomatic individuals. Three patients (P4, P12 and P16) underwent 
HSCT and are alive and well, besides, one patient received liver transplantation (P10). The 
mortality rate among symptomatic patients was 47% (P3, P5, P7, P9, P10, P11, P13 and P15). 
The cause of death was infectious diseases for three patients (disseminated infection by 
Aspergillus for P5, disseminated infection by M. avium for P9 and disseminated infection by 
M. kansasii for P13), hematological diseases for two patients (myelodysplasia for P3 and 
AML for P7), and unknown in two patients (P11 and P15). Fulminant hepatitis associated 
with encephalitis and multiorgan failure caused the death of P10.  
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Figure 30 - First onset of mycobacterial infection in GATA2 patients. Kaplan-Meier curve showing percentage 
of mycobacterial infection free patients in a range of 5 to 45 years. Total number of patients (n=16) is indicated 
by a continuous black line, patients affected by environmental mycobacteria (EM, n=9) are indicated by a 
discontinuous grey line, patients affected by Mycobacterium tuberculosis (TB, n=4) are indicated by a 
discontinuous black line and patients affected by unidentified mycobacteria (Mycobacterium spp., n=3) are 
indicated in a black dotted line. 
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DISCUSSION 
The work of this thesis shows the genetic identification of 20 patients of the 500 
patients without a genetic diagnosis, of which three suffer from MSMD and 17 are GATA2 
deficient. Genetic diagnosis in any germline disease is of utmost importance in order to 
provide a successful treatment and genetic counseling for the affected family.8 In this study, 
we have identified two novel mutations in IFNGR2 that confer a novel form of AR partial 
IFN-γR2 deficiency in three patients suffering from mycobacterial diseases. In addition, we 
have also described a detailed cohort of 17 GATA2 patients with mycobacterial disease as 
their main clinical phenotype, as well as determined for the first time the incomplete clinical 
penetrance of this deficiency. Together, these results have helped diagnose and treat patients 
suffering from mycobacterial diseases.  
 
I. A purely quantitative form of partial recessive IFN-R2 deficiency 
In the first part of this thesis we have reported two novel mutations of IFNGR2 in 
three MSMD patients, one being c.1A>G for P1 and P2 in a Turkish family, and the other 
being c.4delC for P3 in an Indian family. Together, they define a novel form of AR partial 
IFN-γR2 deficiency that is purely quantitative, with surface expression of diminished but 
normal receptor chains, whereas previously reported patients expressed diminished levels of 
receptors on the surface that carried missense mutations. The novelty of this study is the 
definition of a completely novel type of AR partial IFN-γR2 deficiency, caused by mutations 
that impair the amount of surface-expressed receptors, but not the nature of these surface 
receptors. These two IFN-γR2 mutants can be over-expressed, albeit at much lower levels 
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than WT, and their functional activity was severely impaired, although not abolished. Both 
SV40-fibroblasts and EBV-B cells from P1 and P2, and by inference from over-expression 
studies, cells from P3 as well, showed a much more severe impairment of activation of 
STAT1 and GAF than cells from other forms of AR partial IFN-γR2 deficiency. P1 and P2 
fresh leukocyte subsets showed a severe impairment of phosphorylation of STAT1 in naïve 
CD4+ T cells and in MDMs. The cellular phenotype is therefore more severe than that of the 
other known form of AR partial IFN-γR2 deficiency, but less severe than that of complete 
IFN-γR2 deficiency. Therefore, these patients should be treated as AR complete IFN-γR2 
deficient patients. 
Like other patients with AR complete or partial IFN-γR2 deficiency, these patients 
had high plasma concentrations of IFN-γ. Their clinical phenotype appears to be 
intermediate, between that of patients with AR complete deficiency167,177,221,191,214–220 and 
patients with AR partial deficiency due to missense mutations.166,189–191 The three patients 
presented clinical complications after BCG vaccination. P1 also presented multifocal 
osteomyelitis caused by BCG at the age of 5 and 7 years, which was treated; he is now healthy 
at age 9. P2 was treated for the complications after BCG vaccination and is healthy at last 
follow up at age 6 years. P3 died of M. chelonei infection at the age of 5 years. The clinical 
phenotype of these patients, with the possible exception of P2, is thus globally more severe 
than that of other patients with AR partial IFN-γR2 deficiency. HSCT is therefore 
recommended for the two survivors, a treatment generally considered for patients with 
complete but not partial IFN-γR2 deficiency.35,220 P1’s osteomyelitis adds another patient 
with a defect in IFN-γ response to show this type of lesion. As it has been previously 
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suggested, osteomyelitis should be considered a sign to sequence genes involved in the IFN-
γ response.222  
 Our study also shows that non-canonical initiation of translation of IFN-γR2 can 
operate upstream enough in cells lacking the canonical AUG codon upstream the segment 
encoding the signal peptide. This is physiologically and clinically relevant, as these three 
patients have a milder phenotype than complete IFN-R2 deficiency. During translation 
initiation in eukaryotic cells, the small (40S) subunit of the eukaryotic ribosome binds to the 
capped 5’-end of the mRNA. It then migrates, stopping at the first AUG codon in a favorable 
context for translation initiation.223 If the first ATG is mutated or the context is altered, 
translation may occur through re-initiation or context-dependent leaky scanning.175,224–226 In 
the IFNGR2 mRNA, the mutation of the first AUG to a GUG, or the loss of a C at position 
+4, prevents efficient translation initiation at this location. The next AUG codon downstream 
of the start codon is located 238 base pairs downstream, which would cause the loss of the 
leader sequence and 58 aminoacids of the extracellular domain. It has been reported, 
however, that non-AUG codons such as CUG, GUG and ACG, may initiate translation. 
192,198–200 The IFNGR2 gene presents one ACG codon at position c.10, two consecutive CTG 
codons starting at positions c.13 and five consecutive CTG codons starting at position c.25.  
We have shown that codons at position 2, 4, 6 and 8 contribute to the residual 
translation of IFN-γR2 and, in the case of the mutation c.1A>G, that the GUG codon may 
contribute as well to this event. The 19 to 12 of 21 residues left in the signal peptide were 
sufficient for the protein to traffic through the secretory pathway. The residual amounts of 
IFN-γR2 translated and transported to the cell surface were sufficient to enable diminished 
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but not abolished cellular responses to IFN-γ. However, the shorter signal peptide was not as 
efficient as its full-length version, in terms of protein expression on the cell surface. Germline 
mutations of other signal peptides have previously been reported to underlie human genetic 
diseases, impairing protein secretion.227–229 Paradoxically, we found that the total expression 
of IFN-γR2 proteins encoded by the c.1A>G and c.4delC alleles is inversely correlated with 
GAS binding activity upon cell stimulation with IFN-γ. Previous studies in prokaryotic cells 
have shown that protein secretion can be affected by the codon encoding the second 
aminoacid position of the signal peptide.230–232 The shorter signal peptide of proteins encoded 
by c.4delC might thus result in intracellular accumulation of the mutant proteins, thereby 
accounting for lower levels of receptor expression on the cell surface, when compared with 
proteins encoded by c.1A>G. Unfortunately, currently available antibodies do not enable a 
robust detection of IFN-γR2 on the cell surface, preventing us from testing this hypothesis. 
 Re-initiation of translation downstream the first AUG has previously been reported 
for other inborn errors of immunity (such as IFNGR1192, NEMO175, RAG1233,234, FAC235 and 
NBS1236), as well as in other fields of human genetics.237,238,247,239–246 Most of these cases are 
N-terminal frameshift mutations that result in premature stop codons, similar to one of the 
IFNGR2 mutations reported here, c.4delC. In these cases, there is an AUG codon downstream 
the frameshift, where reinitiation of translation has been shown to occur; however, it is not 
the case for the c.4delC mutation. To our knowledge, in only one case, for IFNGR1192, a 
missense mutation affecting the first AUG of the gene was reported, like the other IFNGR2 
mutation reported in this study, c.1A>G. The re-initiation of translation in IFNGR1 was 
reported to take place at downstream AUGs codons, with additional contributions of non-
AUG codons.192 In contrast, we describe a genetic form of human disease due to re-initiation 
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of translation by purely non-AUG codons. Translation in non-AUG codons has already been 
shown to take place in neurodegenerative diseases, cancer and stress response.248 This is the 
first example for inborn errors of immunity. This form affects the function of IFN-γR2 
differently depending on the cell type. This can be explained by the fact that the efficiency 
of re-initiation of translation at a codon downstream from the first AUG is poor and may vary 
from cell type to cell type.223 The inefficiency of downstream codons of the first AUG can 
be due to the different amounts of endoplasmic reticulum and post-translational modification 
procedures across cell types249, as well as differences in the tissue specific profile of transfer-
RNA (t-RNA).200,250 These factors contribute to the observed re-initiation of translation 
downstream from the lost canonical AUG, stressing the importance of this compensatory 
mechanism in human genetics. As reinitiation of translation cannot be predicted in silico, 
mutations that disrupt the canonical AUG should not be considered loss-of-function until 
experimentally proven to be. 251 
 
II. GATA2 deficiency and mycobacterial disease: a comprehensive study  
Autosomal dominant GATA2 deficiency is a pleiotropic disorder associated with a 
broad spectrum of phenotypes, including (i) monocytopenia with susceptibility to atypical 
mycobacteria (monoMAC deficiency),109,115 (ii) familial MDS,108,110,116 (iii) CML or 
AML,110,116 and (iv) Emberger syndrome.111,117,118 Rare patients display isolated 
neutropenia,119 aplastic anemia,120 and isolated NK deficiency.112,121. The clinical features 
typically manifest in the second decade of life, but age at onset ranges from early childhood 
to late adulthood.113 Only five large cohorts of patients have been characterized at the 
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immunological, hematological and clinical levels.113,119,126,127,252 Very few cases of GATA2 
deficiency have been studied in detail at the molecular genetic level, and no large series of 
patients initially diagnosed because of mycobacterial disease (monoMAC deficiency) have 
been published. The outcome of mycobacterial disease in these patients therefore remains 
unclear, despite the many published individual case reports for patients with mycobacterial 
disease.109,112,211,253–257,115,117,121,123,126–128,203 There has been no description of the clinical, 
immunological and hematological manifestations associated with mycobacterial disease in 
these patients, for whom molecular genetic studies are also lacking. For this reason, in the 
second chapter of this thesis, we have focused on an international series of 17 patients from 
14 kindreds in 10 countries with AD GATA2 deficiency and mycobacterial disease. Despite 
the previous description of various patients with this disorder, information about their 
ethnicity is often missing. Our patients are from Brazil, Colombia, France, Germany, Mexico, 
Portugal, Spain, Tunisia, Turkey, and the USA.  
We found 11 germline heterozygous mutations in GATA2 in these 17 patients, one of 
which was previously unknown, the other 10 having already been reported in other patients. 
Of the 150 germline GATA2 alleles reported in the literature, only twelve have been properly 
characterized in vitro, which limits the understanding of the mechanism behind GATA2 
deficiency.108,111,260–262,116,117,122,123,202,211,258,259 We report the biochemical evaluation of 11 
GATA2 alleles in vitro, one of which had never been reported before 
(c.1035_1036insTCTGGCC) and of which only one (p.R330*)262 had been studied 
experimentally before. The protein expression was either unaffected in those mutations that 
were missense or affected by truncation in the case of mutations leading to a premature stop 
codon when compared to the WT. We have also shown, in a luciferase assay system, the 
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ability of WT GATA2 to bind and activate its own promoter, which was already reported by 
Cortes-Lavaud et al.202 The mutant alleles tested were either complete LOF (p.R398W, 
p.R330*, c.599dup, c.915_916del, c.1023del, c.1035_1036insTCTGGCC and c.1099dup) or 
hypomorphic (p.M388T, p.R396Q, p.R396W, and p.R398Q) regarding this binding. 
Differences in terms of function, however, did not correlate with clinical outcome. Patients 
with hypomorphic alleles did not show striking differences in clinical phenotypes when 
compared to the patients carrying LOF alleles. When comparing these patients with other 
patients reported with the same mutations, we found that clinical phenotypes were similar (in 
terms of infections and hematological manifestations), but not identical.119,120,127,128 This 
observation has been previously made by other reports, where clinical outcome differs 
between individuals carrying the same mutation, even between family members.127,263 
As for the mechanism of dominance, our results point towards haploinsufficiency 
being involved. This conclusion is based on (i) the truncating nature of most mutations, (ii) 
the lack of negative dominance in vitro, and (iii) the negative selection operating on GATA2. 
Our results are at odds with a previous report on p.R330*,262 which was proposed to be 
dominant negative. The most likely explanation for this discrepancy is that the experimental 
conditions differed. The use of different promoters, normalization strategies, and transfection 
reagents, might explain the different results. A previous report has established that depending 
on the promoter used for luciferase assay, the same allele can be complete LOF or 
hypomorphic,260 stressing the different roles that GATA2 has as a transcription factor. 
The key clinical presentation in these GATA2-deficient patients is mycobacterial 
disease, principally marked by the high proportion of EM, in particular M. kansasii and M. 
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avium. Interestingly, M. tuberculosis is the second most frequent mycobacterium implicated, 
affecting five patients, probably due to the fact that the affected patients live in countries in 
which this mycobacterium is endemic. No significant differences in terms of mycobacterial 
species and geographic or ethnic origin have been observed, when comparing this cohort 
with other patients reported in the literature.112,123,126–128,203,211,255,256 Complication of BCG 
vaccines was not reported in this cohort, consistent with the low susceptibility to BCG 
documented in other published GATA2-deficient patients.112,128,203 This probably reflects the 
age-dependent decline of immunity in these patients, who showed a progressive loss of 
monocytes, dendritic cells, B cells, NK cells and, in some cases, T cells. Interestingly, one 
patient had an adverse reaction to the yellow fever vaccine, requiring hospitalization. The 
loss of peripheral dendritic cells and in particular plasmacytoid dendritic cells could 
contribute to the adverse effects of this vaccine, as seen in GATA2-deficient patients with 
severe influenza.122 Our patients showed no differences with previously reported patients 
with GATA2 deficiency; who were also prone to develop viral, pyogenic, and fungal 
infections, as well as malignant hematological disorders and non-hematological disorders, 
such as lymphedema.113,126,264 
We observed that clinical penetrance for any GATA2 deficiency-related disease was 
incomplete at the age of 40 years (32.9%), as 16 of the relatives of the index cases were 
carriers of the GATA2 mutations but remained asymptomatic, one of them up to the age of 
78 years. Moreover, we observed that the penetrance for mycobacterial infection was 
incomplete at the age of 40 years (22.6%) and that there were no significant differences 
between the penetrance for mycobacterial disease or for other clinical phenotypes. 
Penetrance for GATA2 deficiency in the literature is not properly characterized, since the 
DISCUSSION 
 Page 123 
    
high but incomplete penetrance for MDS and AML113,119,252,260 and low penetrance for 
lymphedema111,118,128,212,213,263,265 are assumed based on the number of patients affected, 
without performing a proper penetrance analysis. In our study we show, by calculating the 
clinical penetrance of any GATA2 deficiency-associated disease or for mycobacterial disease 
in particular, excluding the index cases, that GATA2 deficiency penetrance increases with 
age but remains, however, incomplete by the age of 40 years. Probably, various factors may 
be involved in this clinical heterogeneity, including gene modifiers in human, environmental 
exposure and type of microbe. We therefore formerly demonstrate the incomplete penetrance 
for GATA2 deficiency, which has been assumed throughout the years but had never been 
properly analyzed.126,213,263,265  
Altogether, GATA2 deficiency is a complex inborn error of hematopoiesis that 
requires further study and characterization, given the differences observed between patients 
and the incomplete penetrance for any GATA2 deficiency-related disease. Search for 
modifier genes and somatic variations may help discern the broad spectrum within this 
deficiency. A diagnosis of AD GATA2 deficiency should be considered in young adults with 
mycobacterial infections, with or without monocytopenia, at any age in life. Moreover, all 
their direct relatives should be genotyped at the GATA2 locus. 
In summary, we have characterized two mutations in IFNGR2 that give place to a 
non-canonical reinitiation of translation of IFN-γR2. This results in a quantitative partial 
deficiency of IFN-γR2 which is more severe than the qualitative partial IFN-γR2 deficiencies 
described to date. Moreover, we have characterized in vitro 11 GATA2 mutations, proving 
their impairment on GATA2 activity. We have described in detail the clinical features of the 
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GATA2-mutation carriers and have made a formal calculation of the clinical penetrance, 
which we observe is incomplete up to 40 years of age.  
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III. Future perspectives 
 a. IFN-γR2 deficiency 
In the novel form of IFN-γR2 deficiency, it is hypothesized that the differences 
observed in terms of response to IFN-γ in overexpression for c.1A>G and c.4delC are due to 
the shorter signal peptide created by c.4delC, causing the possible intracellular accumulation 
of the latter mutant. In order to prove this, two complementary approaches can be followed: 
first, comparing the expression of both mutant IFN-γR2 proteins on the cell surface by flow 
cytometry, and second, to locate both mutant proteins on the cell surface and within the cell 
by microscopy. The available IFN-γR2 antibodies for flow cytometry do not provide a strong 
enough signal to detect slight differences between two lowly expressed IFN-γR2 
proteins.166,167,215 Nonetheless, the subcellular localization of both IFN-γR2 mutants can be 
tested by fluorescent microscopy. By overexpression, both mutants can be marked with an 
anti-flag antibody and their localization be detected in the cell.166 With time and the right 
equipment it is possible to follow this approach.  
Moreover, in this project we have observed a more severe form of IFN-γR2 partial 
deficiency. In previous studies, as well as in this one, it has been observed that each IFNGR2 
hypomorphic mutation responds differently to IFN-γ (in terms of STAT1 phosphorylation) 
and that this response can vary from one cell type to another.166,167,191 It could be interesting 
to study the downstream implications of these differences and rank the mutations from more 
deleterious to less deleterious. To this end, RNA sequencing could be performed after 
activation with IFN-γ in available cell lines from IFN-γR2 partial deficient patients. This can 
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help elucidate the specific effect each mutation has at the signaling level, as well as determine 
the contribution of each cell type to the response to IFN-γ. 
Finally, it is noteworthy that the lack of sufficient biological material from the patient 
with the c.4delC mutation has led to infer our conclusions about it from an overexpression 
system. The use of induced pluripotent stem cells (iPSCs) to study MSMD patients has been 
recently suggested.266 iPSCs can be generated from different sources and can then be 
differentiated into several cells of the hematopoietic lineage, such as macrophages.267,268 
Given this, the available material from the IFN-γR2 deficient patient carrying the c.4delC 
mutation could be used to create iPSCs and study the consequence of the mutation in 
conditions closer to those in vivo.266 
b. GATA2 deficiency 
 In the GATA2 cohort, one of the main observations is that half of the individuals 
carrying a mutation in the GATA2 remain, to the date of this thesis, clinically healthy or 
asymptomatic. Previous studies had already observed this trend, but had never calculated the 
clinical penetrance.126,212 By calculating the clinical penetrance, we have corroborated that, 
indeed, GATA2 deficiency shows incomplete penetrance. However, the incomplete clinical 
penetrance per se requires further investigation. It has been suggested that genetic modifiers 
might play a role in incomplete penetrance for GATA2,212 but this was not properly 
investigated. Another study has pointed towards allele specific expression as the main cause 
for differences in clinical penetrance.213 Al Seraihi and colleagues213 investigated differences 
among GATA2 mutation carriers of a multiplex kindred. In that study they observed that all 
symptomatic individuals carried secondary genetic mutations, but that this was not enough 
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to account for the incomplete penetrance. They then evaluated the endogenous levels of 
GATA2, where they observed that the symptomatic individuals expressed more the mutant 
allele than the WT, as opposed to the asymptomatic carriers. This lead to an allelic imbalance 
in WT:mutant GATA2 ratio, which was shown to be caused by epigenetic mechanisms.213 
Investigating more individuals carrying GATA2 mutations will strengthen these findings and 
might, in the future, help find and alternative treatment to HSCT. 
 Another point worth considering of our study comes from the allele study in 
overexpression system. For our assays we have used embryonic kidney cells, which are quite 
different from the cells where GATA2 acts.113,269 Even though our results in overexpression 
are robust, it could be worth testing the alleles in myeloid cell lines more closely related to 
GATA2, such as U937 cells of HEL-60 cells. However, the use of one of these cell lines 
would require more time and set up, since the allele expression would have to be by viral 
transduction, as opposed to the transient transfection system used for HEK293-T cells.108,202 
 Finally, we have corroborated that GATA2 is expressed in hematopoietic progenitors 
but not in fully differentiated leukocytes.269 It has been observed in mice that GATA2 is most 
important in the cell fate of common myeloid-restricted progenitors, accounting for the lack 
of monocytes and dendritic cells in many patients.270 The evaluation of several hematopoietic 
progenitors has already been performed for other deficiencies, where the gene’s contribution 
could be assessed.271 This assay could be performed in available material from GATA2 
deficient patients, allowing elucidating GATA2’s role in hematopoietic progenitors.
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CONCLUSIONS 
I. A novel form of IFN-γR2 deficiency 
1. Two novel mutations in IFN-γR2, c.1A>G and c.4delC, cause autosomal recessive 
IFN-γR2 partial deficiency. 
2. The mature protein produced by these two mutations is less expressed but its sequence 
is wild type. 
3. The mutations c.1A>G and c.4delC in IFNGR2 give place to reinitiation of translation 
in non-AUG codons within the signal peptide of the protein. 
4. IFN-γR2 deficiency is these two cases is due to a quantity defect of the protein, unlike 
the previously reported autosomal recessive IFN-γR2 partial deficiencies, that display 
a quality defect. 
II. A comprehensive study of GATA2 deficiency 
1. AD GATA2 deficiency is dominant by haploinsufficiency and displays incomplete 
penetrance. 
2. A diagnosis of AD GATA2 deficiency should be considered in patients of any age 
with mycobacterial infections, especially, but not exclusively, in the presence of other 
GATA2 deficiency-related phenotypes, in particular monocytopenia and/or dendritic 
cell deficiency. 
3. All direct relatives of GATA2 deficient patients should be genotyped for the GATA2 
locus. 
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Taken together, these results highlight the importance of characterizing novel 
mutations in known genes. Even if the gene is known, without proper characterization 
the impact of the mutation cannot be ascertained. 
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ANNEXES 
I. SCID and CID causing genes 
Patients with mycobacterial infections have been reported in these PIDs. 
Table 1 – SCID causing genes 
Disease Affected gene Inheritance Protein function Reference 
T-B+ SCID 
    
γc deficiency IL2RG XR Subunit of six 
interleukin receptors 
(IL-2, IL-4, IL-7, IL-
9, IL-15 and IL-21) 
56 
JAK3 deficiency JAK3 AR Signal transducer of 
the γc 
57 
IL-7Rα deficiency IL7R AR Alpha subunit of IL-
7 receptor 
58 
CD45 deficiency PTPRC AR Signaling molecule 
involved in cell 
growth and 
differentiation 
59 
     
T-B- SCID 
    
RAG1 deficiency RAG1 AR Involved in variable, 
diversity, joining 
[V(D)J] 
recombination for 
immunoglobulins 
65 
RAG2 deficiency RAG2 AR Involved in V(D)J 
recombination for 
immunoglobulins 
65 
DCLRE1C deficiency DCLRE1C AR Involved in DNA 
repair and V(D)J 
recombination 
67 
Cernunnos deficiency NHEJ1 AR Involved in DNA 
repair 
69 
ADA deficiency ADA AR Catalyzes the 
irreversible 
deamination of 
adenosine and 
deoxyadenosine in 
66, 72-74 
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the purine catabolic 
pathway 
 
 
Table 2 – CID causing genes 
Disease Affected gene Inheritance Protein function Reference 
CID 
    
DOCK2 deficiency DOCK2 AR Responsible for 
proper chemotaxis 
77 
CD40 ligand 
deficiency 
CD40L X-linked Expressed on T 
cells and 
responsible of T 
cell/APC interaction 
and CD40-
dependent IL-12 
production 
85, 96 
ZAP-70 deficiency ZAP70 AR Interacts with CD3ζ 
in the T cell 
receptor 
98 
MHC class II 
deficiency group A 
CIITA AR MHC class II 
transactivator,maste
r regulator of MHC 
class II gene 
transcription 
99,100 
DOCK8 deficiency DOCK8 AR Involved in actin 
regulation 
101,102 
IKBKB deficiency IKBKB AR Involved in the NF-
κB canonical 
pathway 
78,79 
NIK deficiency MAP3K14 AR NF-κB inducer in 
the non-canonical 
pathway 
80 
     
CID with associated 
syndromic features 
    
Nijmegen breakage 
syndrome 
NBS1 AR Involved in 
repairing double 
strand breaks 
81,82 
POLE2 deficiency POLE2 AR Involved in DNA 
repair and 
replication 
83 
Winged helix nude 
FOXN1 deficiency 
FOXN1 AR Maintains the 
balance between 
84,86 
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growth and 
differentiation of 
the epithelial cells 
of the thymus 
Schimke immuno-
osseous dysplasia 
SMARCAL1 AR Involved in 
chromatin 
remodelation 
87,88 
Calcium channel  
ORAI-1 deficiency 
ORAI1 AR Essential for 
lymphocyte 
activation 
89,90 
PNP deficiency PNP AR Has a key role in 
purine catabolism 
essential for 
maintaining T cell 
survival 
91-93 
NEMO deficiency IKBKG X-linked Involved in the NF-
κB canonical 
pathway 
94,96 
EDA-ID due to 
IKBA mutation 
IKBA AD Gain of function 
mutation of the 
inhibitor of NF-κB, 
IκBα 
95,96 
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II. Selective pressure measures 
Selection Inference using Poisson Random Effects (SnIPRE)180 uses a generalized 
linear mixed model to model genome-wide variability for categories of mutations and 
estimates two key population genetic parameters for each gene among which f quantifies the 
strength of purifying selection acting on human genes, with 0 corresponding to strong 
negative selection and 1 to neutral selection. The alignment of the hg19 human genome and 
the PanTro3 chimp genome from UCSC Genome Browser were used. All differences 
between the two species were annotated functionally by snpEff 50, using the GRCh37.65 
build. All human coding sequences (CDS) >20 base pair (bp) long were retrieved and 
considered, for each gene, the longest transcript available. All polymorphisms identified in 
the WES data of phase 1 of the 1,000 Genomes Project were then retrieved. Single nucleotide 
polymorphisms (SNPs) that were annotated as non-synonymous or synonymous were 
analyzed, outside of gaps in the human-chimp alignment and polymorphic in at least one 
human population. Positions that were actually polymorphic in humans or chimps were 
removed from positions divergent between humans and chimps, using the dbSNP136 chimp 
database. The number of divergent and polymorphic synonymous and nonsynonymous 
mutations were obtained, and the proportion of synonymous and nonsynonymous sites, in a 
total of 18,969 genes. SnIPRE was then used to estimate the f parameter. 
 The Residual Variation Intolerance Score (RVIS)181 uses allele frequency data to rank 
genes in terms of whether they have more or less common functional genetic variation 
relative to the genome wide expectation given the amount of apparently neutral variation the 
gene has. A RVIS close to 0 has a low number of functional variation, while a gene associated 
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with an RVIS close to 1 is subject to a high variation rate. The RVIS values calculated using 
the ExAC dataset were downloaded from the RVIS website. 
The probability of being LOF intolerant (pLI)182 scores the intolerance of each gene to LOF 
variations. The closer pLI is to 1, the more LOF intolerant the gene appears to be. The authors 
consider pLI >= 0.9 as an extremely LOF intolerant set of genes. The pLI scores were 
downloaded from the ExAC website.  
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